• Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients.
    • Guo Y, Wan Q, Ouyang T, Li J, Wang T, Fan Z, Xie Y.
    • Breast. 2022 Oct;65:55-60. doi: 10.1016/j.breast.2022.07.002. Epub 2022 Jul 7.
    • Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.
    • Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, Uliana V, Zanoni D, Tommasi C, Bortesi B, Bonatti F, Piacentini F, Cortesi L, Camisa R, Sgargi P, Michiara M, Musolino A.
    • Breast. 2022 Oct;65:145-150. doi: 10.1016/j.breast.2022.07.012. Epub 2022 Jul 31.
    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25.
    • Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
    • Stodtmann S, Eckert D, Joshi R, Nuthalapati S, Ratajczak CK, Menon R, Mensing S, Xiong H.
    • J Clin Pharmacol. 2022 Oct;62(10):1236-1246. doi: 10.1002/jcph.2061. Epub 2022 May 5.

    Identifier: NCT02163694: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. (ClinicalTrials.gov)

    • Intrathecal Methotrexate Toxicity Resulting in Brain Death due to Generalized Cerebral Edema Case Report.
    • Pang H, Chan JL, Bannykh SI, Gezalian M, Lahiri S, Toossi S, Ayodele M.
    • Neurohospitalist. 2022 Oct;12(4):697-701. doi: 10.1177/19418744221106313. Epub 2022 Jun 6.
    • Case report
    • Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    • Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O.
    • J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595.
    • Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    • Mailliez A, D'Hondt V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel ES, De la Motte Rouge T, Simon G, Jacot W, Delaloge S.
    • Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304. Epub ahead of print.
    • Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer.
    • McCarthy AM, Manning AK, Hsu S, Welch M, Moy B, Lehman CD, Armstrong K.
    • Breast Cancer Res Treat. 2022 Sep 22. doi: 10.1007/s10549-022-06739-5. Epub ahead of print.
    • Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy.
    • Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ.
    • Clin Cancer Res. 2022 Sep 22:CCR-22-1553. doi: 10.1158/1078-0432.CCR-22-1553. Epub ahead of print.
    • Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    • Heemskerk-Gerritsen BAM, Hollestelle A, van Asperen CJ, van den Beek I, van Driel WJ, van Engelen K, Gómez Garcia EB, de Hullu JA, Koudijs MJ, Mourits MJE, Hooning MJ, Boere IA.
    • PLoS One. 2022 Sep 22;17(9):e0275015. doi: 10.1371/journal.pone.0275015.
    • BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
    • Pavese F, Capoluongo ED, Muratore M, Minucci A, Concetta Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, D’Angelo T, Franceschini G, Masetti R, Fabi A, Mulè A, Santoro A, Belli P, Tortora G, Scambia G, Paris I.
    • Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14184571.
    • Patient-Associated Risk Factors for Severe Anemia in Patients with Advanced Ovarian or Breast Cancer Receiving Olaparib Monotherapy: A Multicenter Retrospective Study.
    • Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T.
    • Front Oncol. 2022 Sep 16;12:898150. doi: 10.3389/fonc.2022.898150.
    • Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer.
    • Corso G, Magnoni F, Veronesi P.
    • Ann Surg Oncol. 2022 Sep 15. doi: 10.1245/s10434-022-12542-9. Epub ahead of print.
    • Review
    • Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    • Murphy BL, Yi M, Gutierrez Barrera AM, Tripathy D, Hunt KK, Arun BK.
    • Ann Surg Oncol. 2022 Sep 12. doi: 10.1245/s10434-022-12468-2. Epub ahead of print.
    • Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients.
    • Altundag K.
    • Breast Cancer Res Treat. 2022 Sep 10. doi: 10.1007/s10549-022-06742-w. Epub ahead of print.

    Original research:

    Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer.

    • Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Pinto L, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2022 Sep 9;20(1):34. doi: 10.1186/s13053-022-00242-0.
    • From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
    • De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Franceschini R, Tancredi R, Pedrazzoli P, Santoro A, Zambelli A.
    • Front Pharmacol. 2022 Sep 8;13:909566. doi: 10.3389/fphar.2022.909566.
    • Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.
    • Park SY, Suh KJ, Lee DW, Ryu HS, Kim M, Kim SH, Lee KH, Kim TY, Kim JH, Park IA, Im SA.
    • Breast Cancer Res Treat. 2022 Sep 7. doi: 10.1007/s10549-022-06566-8. Epub ahead of print.
    • Genomics to select treatment for patients with metastatic breast cancer.
    • Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I.
    • Nature. 2022 Sep 7. doi: 10.1038/s41586-022-05068-3. Epub ahead of print.

    Identifier: NCT02299999: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast). (ClinicalTrials.gov)

    Identifier: NCT03386162: SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer (SAFIR-PI3K). (ClinicalTrials.gov)

    • PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
    • Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F.
    • Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
    • A progressive and refractory case of breast cancer with Cowden syndrome.
    • Sueta A, Takeno M, Goto-Yamaguchi L, Tomiguchi M, Inao T, Yamamoto-Ibusuki M, Yamamoto Y.
    • World J Surg Oncol. 2022 Sep 3;20(1):279. doi: 10.1186/s12957-022-02745-5.
    • A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
    • Jia X, Wang K, Xu L, Li N, Zhao Z, Li M.
    • Breast. 2022 Sep 2;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub ahead of print.
    • Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    • Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM.
    • Clin Cancer Res. 2022 Sep 1:CCR-22-0749. doi: 10.1158/1078-0432.CCR-22-0749. Epub ahead of print.

    Identifier: NCT01623349: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer. (ClinicalTrials.gov)

    Identifier: NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC). (ClinicalTrials.gov)

    • Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    • Onji H, Murai J.
    • Cancer Sci. 2022 Sep;113(9):2943-2951. doi: 10.1111/cas.15477. Epub 2022 Jul 16.
    • Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants.
    • Saule C, Menu-Hespel S, Carton M, Malhaire C, Cherel P, Reyal F, Le Mentec M, Guillot E, Donnadieu A, Callet N, Frank S, Coussy F, Stoppa-Lyonnet D, Mouret-Fourme E.
    • Eur J Hum Genet. 2022 Sep;30(9):1060-1066. doi: 10.1038/s41431-022-01049-2. Epub 2022 Feb 25.
    • HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report.
    • Mabuchi Y, Hamano Y, Minami S, Ota N, Ino K.
    • Oncol Lett. 2022 Jul 27 [eCollection 2022 Sep];24(3):325. doi: 10.3892/ol.2022.13445.
    • Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology.
    • van der Wiel AMA, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A, Dubois LJ.
    • Cancers (Basel). 2022 Aug 27;14(17):4157. doi: 10.3390/cancers14174157.
    • Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
    • Boni V, Pistilli B, Braña I, Shapiro GI, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah V.
    • ESMO Open. 2022 Aug 26;7(5):100571. doi: 10.1016/j.esmoop.2022.100571. Epub ahead of print.

    Identifier: NCT02454972: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors. (ClinicalTrials.gov)

    • Eligibility, uptake and response to germline genetic testing in women with DCIS.
    • Turza L, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Front Oncol. 2022 Aug 26;12:918757. doi: 10.3389/fonc.2022.918757.
    • PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.
    • Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J, Chen H, Zhao X, Yang L, Lu H.
    • Front Pharmacol. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633.
    • Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
    • Garufi G, Carbognin L, Schettini F, Seguí E, Di Leone A, Franco A, Paris I, Scambia G, Tortora G, Fabi A.
    • Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
    • A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    • Zeng T, Sun C, Liang Y, Yang F, Yan X, Bao S, Zhang Y, Huang X, Fu Z, Li W, Yin Y.
    • Cancers (Basel). 2022 Aug 23;14(17):4084. doi: 10.3390/cancers14174084.
    • Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
    • Leung JH, Tai YS, Wang SY, Tsung-Chin H, Yip FH, Chan AL, Yu-Chen H.
    • Expert Opin Drug Saf. 2022 Aug 23. doi: 10.1080/14740338.2022.2116001. Epub ahead of print.
    • Meta-Analysis
    • PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
    • Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV.
    • Mol Cancer Ther. 2022 Aug 23:MCT-22-0217. doi: 10.1158/1535-7163.MCT-22-0217. Epub ahead of print.
    • Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
    • Baranwal A, Hahn CN, Shah MV, Hiwase DK.
    • Curr Hematol Malig Rep. 2022 Aug 20. doi: 10.1007/s11899-022-00676-2. Epub ahead of print.
    • Review
    • Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol.
    • Liao H, Pei W, Zhong J, Li H.
    • BMJ Open. 2022 Aug 18;12(8):e059538. doi: 10.1136/bmjopen-2021-059538.
    • Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
    • Lucas MW, Kelly CM.
    • Cancer Manag Res. 2022 Aug 17;14:2493-2506. doi: 10.2147/CMAR.S341466.
    • Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study.
    • Wang N, Yu X.
    • Front Immunol. 2022 Aug 15;13:901636. doi: 10.3389/fimmu.2022.901636.
    • Targeted therapy for breast cancer: An overview of drug classes and outcomes.
    • Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L.
    • Biochem Pharmacol. 2022 Aug 13:115209. doi: 10.1016/j.bcp.2022.115209. Epub ahead of print.
    • Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients.
    • Fasching PA, Liu D, Scully S, Ingle JN, Lyra PC, Rack B, Hein A, Ekici AB, Reis A, Schneeweiss A, Tesch H, Fehm TN, Heinrich G, Beckmann MW, Ruebner M, Huebner H, Lambrechts D, Madden E, Shen J, Romm J, Doheny K, Jenkins GD, Carlson EE, Li L, Fridley BL, Cunningham JM, Janni W, Monteiro ANA, Schaid DJ, Häberle L, Weinshilboum RM, Wang L.
    • Clin Cancer Res. 2022 Aug 2;28(15):3342-3355. doi: 10.1158/1078-0432.CCR-20-4774.
    • Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    • Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard FC, Richard F, Yang WW, Steele RE, Pettitt SJ, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-Salomon A, Derksen PWB, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C.
    • Ann Oncol. 2022 Aug;33(8):769-785. doi: 10.1016/j.annonc.2022.05.006. Epub 2022 May 21.
    • Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.
    • Shubeck S, Sevilimedu V, Berger E, Robson M, Heerdt AS, Pilewskie ML.
    • Ann Surg Oncol. 2022 Aug;29(8):4706-4713. doi: 10.1245/s10434-022-11756-1. Epub 2022 May 18.

    Commentary:

    A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.

    ASO Visual Abstract: Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery and Those Treated With Mastectomy. (Annals of Surgical Oncology)

    • Surgical management of BRCA-mutation carriers: A single institution experience.
    • Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, Testori A, Errico V, Bianchi P, Biondi E, Torrisi R, Santoro A, Tinterri C.
    • Eur J Surg Oncol. 2022 Aug;48(8):1706-1712. doi: 10.1016/j.ejso.2022.04.024. Epub 2022 Apr 30.
    • Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
    • Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ.
    • Nat Cancer. 2022 Aug;3(8):927-931. doi: 10.1038/s43018-022-00400-2. Epub 2022 Jul 4. Erratum in: Nat Cancer. 2022 Aug 5.

    Identifier: NCT03329937: Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer. (ClinicalTrials.gov)

    • The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point.
    • Kalinowski L, Viale G, Domchek S, Tutt A, Lucas PC, Lakhani SR.
    • Pathology. 2022 Aug;54(5):511-516. doi: 10.1016/j.pathol.2022.05.003. Epub 2022 Jun 29.
    • Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    • Kotani H, Masuda N, Yamashita T, Naito Y, Taira T, Inoue K, Takahashi M, Yonemori K, Toyoizumi S, Mori Y, Nagasawa T, Hori N, Iwata H.
    • Breast Cancer. 2022 Jul 30. doi: 10.1007/s12282-022-01390-w. Epub ahead of print.

    Identifier: NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors. (ClinicalTrials.gov)

    • PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
    • Kim D, Nam HJ.
    • Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412.
    • High grade acinic cell carcinoma of the breast with clear cytoplasm mimics clear cell carcinoma in a BRCA1 mutation carrier: a case report and review of the literature on the molecular analysis.
    • Min L, Qiao H, Hongkai Z.
    • Histol Histopathol. 2022 Jul 27:18501. doi: 10.14670/HH-18-501. Epub ahead of print.
    • Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants.
    • Edaily S, Abdel-Razeq H.
    • Onco Targets Ther. 2022 Jul 27;15:815-826. doi: 10.2147/OTT.S369844.
    • Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: a case report.
    • Gomez-Puerto D, Llop-Guevara A, Torres-Esquius S, Cruellas M, De la Torre J, Peg V, Balmaña J, Pimentel I.
    • Front Oncol. 2022 Jul 26;12:963728. doi: 10.3389/fonc.2022.963728.
    • Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    • de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
    • J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.
    • Wu S, Qi L, Chen H, Zhang K, He J, Guo X, Shen L, Zhou Y, Zhong X, Zheng S, Zhou J, Chen Y.
    • NPJ Breast Cancer. 2022 Jul 19;8(1):86. doi: 10.1038/s41523-022-00454-6.
    • Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
    • Yoder R, Kimler BF, Staley JM, Schwensen K, Wang YY, Finke K, O'Dea A, Nye L, Elia M, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Shrestha A, Corum L, Marsico M, Stecklein SR, Godwin AK, Khan QJ, Sharma P.
    • NPJ Breast Cancer. 2022 Jul 11;8(1):80. doi: 10.1038/s41523-022-00448-4.
    • Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer.
    • Pauls M, Chia S, LeVasseur N.
    • Curr Oncol. 2022 Jul 7;29(7):4748-4767. doi: 10.3390/curroncol29070377.
    • Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
    • MacDonald I, Nixon NA, Khan OF.
    • Curr Oncol. 2022 Jul 7;29(7):4768-4778. doi: 10.3390/curroncol29070378.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.
    • Yoshimura A, Imoto I, Iwata H.
    • Int J Mol Sci. 2022 Jul 5;23(13):7481. doi: 10.3390/ijms23137481.
    • An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome.
    • Gonçalves D, Pires AS, Marques IA, Gomes I, Sousa G, Botelho MF, Abrantes AM.
    • Cancers (Basel). 2022 Jul 2;14(13):3254. doi: 10.3390/cancers14133254.
    • New Adjuvant Treatment for High-Risk Early Breast Cancer.
    • Aschenbrenner DS.
    • Am J Nurs. 2022 Jul 1;122(7):26. doi: 10.1097/01.NAJ.0000842240.11650.1d.
    • News
    • A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation.
    • Toesca A, Sangalli C, Maisonneuve P, Massari G, Girardi A, Baker JL, Lissidini G, Invento A, Farante G, Corso G, Rietjens M, Peradze N, Gottardi A, Magnoni F, Bottiglieri L, Lazzeroni M, Montagna E, Labo P, Orecchia R, Galimberti V, Intra M, Sacchini V, Veronesi P.
    • Ann Surg. 2022 Jul 1;276(1):11-19. doi: 10.1097/SLA.0000000000004969. Epub 2021 Jun 9.

    Identifier: NCT03440398: Robotic Nipple-Sparing Mastectomy Vs Conventional Open Technique. (ClinicalTrials.gov)

    Commentary:

    Editorial on Toesca et al's "A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BRCA Mutation".

    • Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University.
    • Oranratnachai S, Yamkaew W, Tunteeratum A, Sukarayothin T, Iemwimangsa N, Panvichien R.
    • Cancer Rep (Hoboken). 2022 Jul 1:e1664. doi: 10.1002/cnr2.1664. Epub ahead of print.
    • Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery.
    • Magnoni F, Sacchini V, Veronesi P, Bianchi B, Bottazzoli E, Tagliaferri V, Mazzotta E, Castelnovo G, Deguidi G, Rossi EMC, Corso G.
    • Cancers (Basel). 2022 Jul 1;14(13):3245. doi: 10.3390/cancers14133245.
    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.
    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
    • Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Rørth M, Ejlertsen B, Lash TL, Ahern TP, Sørensen HT, Cronin-Fenton D.
    • Breast Cancer Res Treat. 2022 Jul;194(2):353-363. doi: 10.1007/s10549-022-06596-2. Epub 2022 Apr 30.
    • Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.
    • van Barele M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, Koppert LB, Loo CE, Tollenaar RAEM, Ausems MGEM, van de Beek I, Berger LPV, de Boer M, van Hest LP, Kets CM, Rookus M; Hebon, Schmidt MK, Jager A, Hooning MJ.
    • Breast Cancer Res Treat. 2022 Jul;194(1):159-170. doi: 10.1007/s10549-022-06608-1. Epub 2022 May 4.
    • The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    • Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, Gronwald J, Stawicka M, Godlewski D, Kilar E, Marczyk E, Siolek M, Wisniowski R, Haus O, Sibilski R, Bodnar L, Sun P, Narod SA, Lubinski J, Huzarski T; Polish Breast Cancer Consortium.
    • Br J Cancer. 2022 Jul;127(1):84-91. doi: 10.1038/s41416-022-01770-1. Epub 2022 Mar 7.
    • Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    • Wang X, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P.
    • Curr Cancer Drug Targets. 2022 [Jul];22(6):530-536. doi: 10.2174/1568009622666220214092207.
    • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    • McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B.
    • Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.
    • Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation.
    • Zarbiv Y, Wygoda YB, Grinshpun A, Hamburger T, Sella T, Breuer S, Maimon O, Rottenberg Y, Peretz T, Kadouri L.
    • Oncol Ther. 2022 Jun 25. doi: 10.1007/s40487-022-00202-7. Epub ahead of print.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Jun 18. doi: 10.1245/s10434-022-12048-4. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer.
    • Rutherford CL, Goodman D, Lannigan A.
    • Eur J Surg Oncol. 2022 Jun 10:S0748-7983(22)00488-7. doi: 10.1016/j.ejso.2022.06.004. Epub ahead of print.
    • Review
    • Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.
    • Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Thomssen C, Witzel I, Fehm TN, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf AD, Wöckel A, Seliger B, Massa C, Kolberg HC.
    • Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):580-589. doi: 10.1055/a-1811-6106.
    • Are Mutation Carrier Patients Different from Non-Carrier Patients? Genetic, Pathology, and US Features of Patients with Breast Cancer.
    • Pintican RM, Chiorean A, Duma M, Feier D, Szep M, Eniu D, Goidescu I, Dudea S.
    • Cancers (Basel). 2022 Jun 2;14(11):2759. doi: 10.3390/cancers14112759.
    • The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    • Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D'Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB.
    • Ann Surg Oncol. 2022 Jun;29(6):3810-3819. doi: 10.1245/s10434-022-11367-w. Epub 2022 Mar 5.
    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
    • Pomerantz A, Tsoref D, Grubstein A, Wadhawker S, Rapson Y, Gadiel I, Goldvaser H, Feldhamer I, Hammerman A, Shochat T, Sharon E, Kedar I, Yerushalmi R.
    • Breast Cancer Res Treat. 2022 Jun;193(2):507-514. doi: 10.1007/s10549-021-06498-9. Epub 2022 Apr 7.
    • PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
    • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, Tunon de Lara C, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N.
    • Cancer Genet. 2022 Jun;264-265:8-15. doi: 10.1016/j.cancergen.2022.02.008. Epub 2022 Feb 25.
    • Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    • Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC.
    • Clin Breast Cancer. 2022 Jun;22(4):319-325. doi: 10.1016/j.clbc.2021.12.007. Epub 2021 Dec 30.
    • Q and A: A New Standard of Care for Germline BRCA1 and/or BRCA2 Mutation Carriers With Early-Stage Breast Cancer.
    • Desai NV, Zakalik D, Somerfield MR, Tung NM.
    • JCO Oncol Pract. 2022 Jun;18(6):427-429. doi: 10.1200/OP.21.00770. Epub 2022 Jan 7.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?
    • Boulos M, Moujaes E, Nsouli G, Tfayli A, Kourie HR.
    • Pharmacogenomics. 2022 Jun;23(8):487-492. doi: 10.2217/pgs-2022-0011. Epub 2022 May 24.
    • Review
    • Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results.
    • Ong SS, Ho PJ, Khng AJ, Lim EH, Wong FY, Tan BK, Lim SH, Tan EY, Tan SM, Tan VKM, Dent R, Tan TJY, Ngeow J, Madhukumar P, Hamzah JLB, Sim Y, Lim GH, Pang JS, Alcantara VS, Chan PMY, Chen JJC, Kuah S, Seah JCM, Buhari SA, Tang SW, Ng CWQ, Li J, Hartman M.
    • Cancers (Basel). 2022 May 31;14(11):2714. doi: 10.3390/cancers14112714.
    • Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?
    • Boulos M, Moujaes E, Nsouli G, Tfayli A, Kourie HR.
    • Pharmacogenomics. 2022 May 24. doi: 10.2217/pgs-2022-0011. Epub ahead of print.
    • Review
    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.
    • Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis.
    • Park HS, Lee J, Lai HW, Park JM, Ryu JM, Lee JE, Kim JY, Marrazzo E, De Scalzi AM, Corso G, Montemurro F, Gazzetta G, Pozzi G, Toesca A.
    • Ann Surg Oncol. 2022 May 18. doi: 10.1245/s10434-022-11865-x. Epub ahead of print.
    • Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
    • Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT.
    • NPJ Breast Cancer. 2022 May 10;8(1):64. doi: 10.1038/s41523-022-00427-9.
    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.
    • Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
    • Miller RS, Mokiou S, Taylor A, Sun P, Baria K.
    • Breast Cancer Res Treat. 2022 May;193(1):83-94. doi: 10.1007/s10549-022-06541-3. Epub 2022 Feb 22.
    • A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    • Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team.
    • Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18.
    • Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
    • BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1.
    • No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients-A 10-Year Follow-Up Study in the Polish Population.
    • Toton E, Jacczak B, Barczak W, Jagielski P, Gryczka R, Holysz H, Grodecka-Gazdecka S, Rubis B.
    • Genes (Basel). 2022 Apr 21;13(5):729. doi: 10.3390/genes13050729.
    • Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients.
    • Hu L, Sun J, Li Z, Qu Z, Liu Y, Wan Q, Liu J, Ding X, Zang F, Zhang J, Yao L, Xu Y, Wang Y, Xie Y.
    • NPJ Breast Cancer. 2022 Apr 21;8(1):52. doi: 10.1038/s41523-022-00417-x.
    • Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review.
    • Kaubryte J, Lai AG.
    • NPJ Precis Oncol. 2022 Apr 20;6(1):27. doi: 10.1038/s41698-022-00269-5.
    • Choroidal Metastasis With Secondary Retinal Detachment in a Man With BCRA2-Associated Breast Adenocarcinoma.
    • Sanayei N, Davoudi S, Port A, Chen X.
    • Cureus. 2022 Apr 18;14(4):e24243. doi: 10.7759/cureus.24243.
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Apr 18. doi: 10.1080/13543784.2022.2067527. Epub ahead of print.
    • Review
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    • Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL.
    • Clin Cancer Res. 2022 Apr 14;28(8):1493-1499. doi: 10.1158/1078-0432.CCR-21-3045.
    • Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer.
    • Zhang J, Wang N, Zheng T, Lu T, Zhang R, Ran R, Li K, Huang Y, Xie F, Zhang Y, Jia S, Yu J, Li H.
    • Front Oncol. 2022 Apr 13;12:745796. doi: 10.3389/fonc.2022.745796.
    • PARP inhibition in breast cancer: progress made and future hopes.
    • Tung N, Garber JE.
    • NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
    • Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
    • Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK.
    • NPJ Breast Cancer. 2022 Apr 7;8(1):46. doi: 10.1038/s41523-022-00407-z.
    • Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    • Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.
    • Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.
    • Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
    • Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
    • Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmaña J.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350232.
    • Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    • Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH.
    • Breast. 2022 Apr;62:52-60. doi: 10.1016/j.breast.2022.01.014. Epub 2022 Jan 29.
    • Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    • Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, Yang K, Wu HC, Chao TY, Chang YC, Lin PC, Kuo WH, Kuo WL, Lin CH, Chen HM, Yeh DC, Liu LC, Liu CY, Wang MY, Lo C, Lu YS, Huang CS.
    • Breast Cancer Res Treat. 2022 Apr;192(3):629-637. doi: 10.1007/s10549-021-06446-7. Epub 2022 Feb 3.
    • Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
    • Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V.
    • ESMO Open. 2022 Apr;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub 2022 Feb 26. Erratum in: ESMO Open. 2022 Apr 7;7(3):100472.
    • First international workshop of the ATM and cancer risk group (4-5 December 2019).
    • Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L; Spanish ATM working group, Arun B, Herold N, Versmold B, Schmutzler RK; GC-HBOC, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE; CARRIERS and Ambry Groups, Stoppa-Lyonnet D, Andrieu N.
    • Fam Cancer. 2022 Apr;21(2):211-227. doi: 10.1007/s10689-021-00248-y. Epub 2021 Jun 14.
    • Conference report
    • Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    • Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E.
    • NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1.
    • PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients' CTCs.
    • Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A, Vasilopoulos Y, Kallergi G.
    • Cancers (Basel). 2022 Mar 29;14(7):1731. doi: 10.3390/cancers14071731.
    • BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.
    • Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ.
    • Int J Mol Sci. 2022 Mar 29;23(7):3754. doi: 10.3390/ijms23073754.
    • Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.
    • Valente PMS, Gomes MCB, Martins WA, Castilho SR.
    • J Oncol Pharm Pract. 2022 Mar 23:10781552221080081. doi: 10.1177/10781552221080081. Epub ahead of print.
    • Case report
    • Olaparib in gBRCA+ Breast Cancer; 'Clearly Practice Changing'.
    • Worcester S.
    • Medscape Oncology. 2022 Mar 18.
    • Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing.
    • Hopkins C.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Mar 17.
    • News

    Clinical Trials: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). (ClinicalTrials.gov)

    Guideline: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) — Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. (National Comprehensive Cancer Network)

    • U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
    • Arora S, Narayan P, Osgood CL, Wedam S, Prowell TM, Gao JJ, Shah M, Krol D, Wahby S, Royce M, Ghosh S, Philip R, Ison G, Berman T, Brus C, Bloomquist EW, Fiero MH, Tang S, Pazdur R, Ibrahim A, Amiri-Kordestani L, Beaver JA.
    • Clin Cancer Res. 2022 Mar 15;28(6):1072-1086. doi: 10.1158/1078-0432.CCR-21-2600.
    • Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer with or without or with Unknown BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and Four EU Countries.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Breast Care (Basel). 2022 Mar 11. doi: 10.1159/000523970. Epub ahead of print.
    • FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Regulatory News. 2022 Mar 11.
    • Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum.
    • Musaddaq B, Brown A, Dluzewski S, Marafioti T, Malhotra A.
    • BJR Case Rep. 2022 Mar 9;7(6):20210063. doi: 10.1259/bjrcr.20210063.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 Mar 4:ijgc-2021-003116. doi: 10.1136/ijgc-2021-003116. Epub ahead of print.
    • Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
    • Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0.
    • BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.
    • Fu X, Tan W, Song Q, Pei H, Li J.
    • Front Cell Dev Biol. 2022 Mar 1;10:813457. doi: 10.3389/fcell.2022.813457.
    • Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    • Han HS, Arun BK, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bach BA, Kundu MG, Khandelwal N, Feng D, Bhattacharya S, Maag D, Ratajczak CK, Diéras V.
    • Ann Oncol. 2022 Mar;33(3):299-309. doi: 10.1016/j.annonc.2021.11.018. Epub 2021 Nov 30.
    • Surgery and prophylactic surgery in hereditary breast cancer.
    • Morrow M.
    • Breast. 2022 Mar;62 Suppl 1:S63-S66. doi: 10.1016/j.breast.2021.12.010. Epub 2021 Dec 13.
    • Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    • Bernini M, Meattini I, Saieva C, Becherini C, Salvestrini V, Visani L, Stocchi G, Bellini C, Lorenzetti V, Sordi S, Nori J, De Benedetto D, Desideri I, Bianchi S, Livi L, Orzalesi L.
    • Breast Cancer. 2022 Mar;29(2):302-313. doi: 10.1007/s12282-021-01314-0. Epub 2021 Nov 14.
    • Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    • Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang X, Zhou X, Cao X, Sun Q.
    • Breast Cancer. 2022 Mar;29(2):314-323. doi: 10.1007/s12282-021-01312-2. Epub 2021 Nov 11.
    • Meta-Analysis
    • Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    • Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y.
    • Breast Cancer. 2022 Mar;29(2):368-376. doi: 10.1007/s12282-021-01319-9. Epub 2022 Jan 5.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • A review on mechanisms of resistance to PARP inhibitors.
    • Desai C, Pathak A, Limaye S, Maniar V, Joshi A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S119-S129. doi: 10.4103/ijc.IJC_53_21.
    • Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
    • Vaid AK, Deshmukh C, Rohatgi N, Ghosh J.
    • Indian J Cancer. 2022 Mar;59(Supplement):S130-S141. doi: 10.4103/ijc.IJC_30_21.
    • Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
    • Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V.
    • JCO Precis Oncol. 2022 Mar;6:e2100140. doi: 10.1200/PO.21.00140.
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • Post-Neoadjuvant Treatment Strategies in Breast Cancer.
    • Matuschek C, Jazmati D, Bölke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckhäberle E, Fehm T, Nestle Krämling C, Dommach M, Haussmann J.
    • Cancers (Basel). 2022 Feb 28;14(5):1246. doi: 10.3390/cancers14051246.
    • Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
    • Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z.
    • Cancers (Basel). 2022 Feb 28;14(5):1253. doi: 10.3390/cancers14051253.
    • Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis.
    • Nara M, Ishihara S, Kitano A, Tamura N, Aruga T, Kobayashi D, Nakamura S, Yamauchi H.
    • Breast Cancer. 2022 Feb 25. doi: 10.1007/s12282-022-01343-3. Epub ahead of print.
    • Meta-Analysis
    • PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
    • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, de Lara CT, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N.
    • Cancer Genet. 2022 Feb 24. doi: 10.1016/j.cancergen.2022.02.008. Epub ahead of print.
    • Quality of life for people with early-stage breast cancer.
    • [No author given]
    • FORCE. XRAY. 2022 Feb 22.
    • Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    • Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
    • J Pers Med. 2022 Feb 21;12(2):323. doi: 10.3390/jpm12020323.
    • RNA Interference Induces BRCA1 Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells.
    • Shi Y, Huang R, Zhang Y, Feng Q, Pan X, Wang L.
    • Cancer Biother Radiopharm. 2022 Feb 18. doi: 10.1089/cbr.2021.0346. Epub ahead of print.
    • Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
    • Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.
    • Eur J Med Chem. 2022 Feb 15;230:114109. doi: 10.1016/j.ejmech.2022.114109. Epub 2022 Jan 12.
    • Review
    • BRCA1/2 Mutations and Cardiovascular Function in Breast Cancer Survivors.
    • Demissei BG, Lv W, Wilcox NS, Sheline K, Smith AM, Sturgeon KM, McDermott-Roe C, Musunuru K, Lefebvre B, Domchek SM, Shah P, Ky B.
    • Front Cardiovasc Med. 2022 Feb 15;9:833171. doi: 10.3389/fcvm.2022.833171.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
    • Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI.
    • JCO Precis Oncol. [2022 Feb 9];6:e2100456. doi: 10.1200/PO.21.00456.
    • Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    • Landry I, Sumbly V, Vest M.
    • Cureus. 2022 Feb 7;14(2):e21970. doi: 10.7759/cureus.21970.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.
    • Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
    • Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M; HEBON Investigators, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
    • Breast. 2022 Feb;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.
    • Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.
    • Thomssen C, Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Belleville E, Bader S, Untch M, Welslau M, Thill M, Hartkopf AD, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R.
    • Geburtshilfe Frauenheilkd. 2022 Feb 11 [eCollection 2022 Feb];82(2):206-214. doi: 10.1055/a-1724-9639.
    • Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer.
    • Nañez A, Stram DA, Bethan Powell C, Garcia C.
    • Gynecol Oncol Rep. 2021 Dec 4 [eCollection 2022 Feb];39:100899. doi: 10.1016/j.gore.2021.100899.
    • PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
    • Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B.
    • Cancers (Basel). 2022 Jan 25;14(3):599. doi: 10.3390/cancers14030599.
    • Real-world evidence of the management and prognosis of young women (<40 years) with de novo metastatic breast cancer.
    • Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, De La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Sébastien Frenel J.
    • Ther Adv Med Oncol. 2022 Jan 21;14:17588359211070362. doi: 10.1177/17588359211070362.
    • Platinum-based systematic therapy in triple-negative breast cancer.
    • Zhu Y, Hu Y, Tang C, Guan X, Zhang W.
    • Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678. doi: 10.1016/j.bbcan.2022.188678. Epub 2022 Jan 10.
    • Review
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    • Bouferraa Y, Haibe Y, Chedid A, Jabra E, Charafeddine M, Temraz S, Mukherji D, El Saghir N, Shamseddine A.
    • BMC Cancer. 2022 Jan 3;22(1):27. doi: 10.1186/s12885-021-09100-z.
    • Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.
    • Patel A, Garcia-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A.
    • Cancer Res. 2022 Jan 1;82(1):25-35. doi: 10.1158/0008-5472.CAN-21-1207. Epub 2021 Oct 28.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Zuo K, Yuan X, Liang X, Sun X, Liu S, Connell PP, Li X, Yang W.
    • Breast Cancer Res Treat. 2022 Jan;191(2):335-344. doi: 10.1007/s10549-021-06442-x. Epub 2021 Nov 19.
    • Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    • Zheng F, Du F, Wang W, Wang Y, Li M, Zhao J, Wang X, Yue J, Wang J, Yang Z, Cai R, Ma F, Fan Y, Li Q, Zhang P, Xu B, Yuan P.
    • Breast Cancer Res Treat. 2022 Jan;191(1):97-105. doi: 10.1007/s10549-021-06401-6. Epub 2021 Oct 14.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    • Vidra R, Nemes A, Vidrean A, Pintea S, Tintari S, Deac A, Ciuleanu T.
    • Exp Ther Med. 2022 Jan;23(1):91. doi: 10.3892/etm.2021.11014. Epub 2021 Nov 26.
    • Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    • John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I.
    • Gynecol Oncol. 2022 Jan;164(1):202-207. doi: 10.1016/j.ygyno.2021.10.077. Epub 2021 Nov 30.
    • Metabolism-related pharmacokinetic drug-drug interactions with poly (ADP-ribose) polymerase inhibitors (Review).
    • Zhao D, Long X, Wang J.
    • Oncol Rep. 2022 Jan;47(1):20. doi: 10.3892/or.2021.8231. Epub 2021 Nov 23.
    • Review
    • Homologous Recombination Deficiencies and Hereditary Tumors.
    • Yamamoto H, Hirasawa A.
    • Int J Mol Sci. 2021 Dec 29;23(1):348. doi: 10.3390/ijms23010348.
    • BRCA1 and Metastasis: Outcome of Defective DNA Repair.
    • Krishnan R, Patel PS, Hakem R.
    • Cancers (Basel). 2021 Dec 27;14(1):108. doi: 10.3390/cancers14010108.
    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • The Role of US in Depicting Axillary Metastasis in High-Risk Breast Cancer Patients.
    • Pintican R, Duma MM, Szep M, Feier D, Eniu D, Goidescu I, Chiorean A.
    • J Pers Med. 2021 Dec 16;11(12):1379. doi: 10.3390/jpm11121379.
    • Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial.
    • Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V.
    • Ther Adv Med Oncol. 2021 Dec 9;13:17588359211059601. doi: 10.1177/17588359211059601.
    • Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
    • Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X.
    • Front Pharmacol. 2021 Dec 6;12:770663. doi: 10.3389/fphar.2021.770663.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.
    • Germline breast cancer susceptibility genes, tumor characteristics, and survival.
    • Ho PJ, Khng AJ, Loh HW, Ho WK, Yip CH, Mohd-Taib NA, Tan VKM, Tan BK, Tan SM, Tan EY, Lim SH, Jamaris S, Sim Y, Wong FY, Ngeow J, Lim EH, Tai MC, Wijaya EA, Lee SC, Chan CW, Buhari SA, Chan PMY, Chen JJC, Seah JCM, Lee WP, Mok CW, Lim GH, Woo E, Kim SW, Lee JW, Lee MH, Park SK, Dunning AM, Easton DF, Schmidt MK, Teo SH, Li J, Hartman M.
    • Genome Med. 2021 Dec 2;13(1):185. doi: 10.1186/s13073-021-00978-9.
    • A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
    • Pavone G, Motta L, Martorana F, Motta G, Vigneri P.
    • Molecules. 2021 Dec 1;26(23):7294. doi: 10.3390/molecules26237294.
    • PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    • Fuentes-Antrás J, Cescon DW.
    • Ann Oncol. 2021 Dec;32(12):1460-1462. doi: 10.1016/j.annonc.2021.10.005. Epub 2021 Oct 19.
    • Commentary
    • Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V.
    • Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
    • ASO Visual Abstract: How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
    • Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, Nguyen A, Oseni T, Specht M, Coopey SB, Gadd MA, Smith BL.
    • Ann Surg Oncol. 2021 Dec;28(Suppl 3):594-595. doi: 10.1245/s10434-021-10583-0.
    • Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
    • Sun X, Wang X, Zhang J, Zhao Z, Feng X, Liu L, Ma Z.
    • Breast. 2021 Dec;60:26-34. doi: 10.1016/j.breast.2021.08.009. Epub 2021 Aug 21.
    • Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
    • Yang Y, Pan L, Shao Z.
    • Breast Cancer Res Treat. 2021 Dec;190(3):503-515. doi: 10.1007/s10549-021-06397-z. Epub 2021 Sep 23.
    • Influence of germline BRCA genotype on the survival of patients with triple-negative breast cancer.
    • Villarreal-Garza C, Ferrigno AS, Aranda-Gutierrez A, Frankel PH, Ruel NH, Fonseca A, Narod S, Chavarri-Guerra Y, Sifuentes E, Magallanes-Hoyos MC, Herzog J, Castillo D, Alvarez-Gomez RM, Mohar-Betancourt A, Weitzel JN.
    • Cancer Res Commun. 2021 Dec;1(3):140-147. doi: 10.1158/2767-9764.crc-21-0099. Epub 2021 Dec 8.
    • Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    • Sakach E, O'Regan R, Meisel J, Li X.
    • Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17.
    • Review
    • Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    • Patsouris A, Diop K, Tredan O, Nenciu D, Gonçalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Droin N, Bièche I, Callens C, Loehr A, Vicier C, Guerin C, Filleron T, André F.
    • Eur J Cancer. 2021 Dec;159:283-295. doi: 10.1016/j.ejca.2021.09.028. Epub 2021 Nov 25.
    • [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
    • Nakagawa T, Oda G, Okamoto K, Ishikawa T, Wakana K, Oshima N.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1556-1558. Japanese.
    • Case report. [Article in Japanese]
    • [Two Cases of Hereditary Breast Cancer in Which Genetic Counseling Was Useful].
    • Sasaki A, Nagata T, Okamoto Y, Watanabe M, Saida Y.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1589-1591. Japanese.
    • Case report. [Article in Japanese]
    • [A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy].
    • Suzuki T, Hashimoto N, Yokoyama K, Yoshida T, Yamauchi Y, Sawano T, Ohashi M, Kimura A, Kato M, Umehara Y, Murata A, Takahash K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1840-1842. Japanese.
    • Case report. [Article in Japanese]
    • [Hereditary Breast and Ovarian Cancer(HBOC)in a Young Adult-A Case Report].
    • Adachi K, Kubota H, Suzuki S, Hirano T, Ishibashi N, Sakurai K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1843-1845. Japanese.
    • Case report. [Article in Japanese]
    • Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
    • Naito Y, Kuboki Y, Ikeda M, Harano K, Matsubara N, Toyoizumi S, Mori Y, Hori N, Nagasawa T, Kogawa T.
    • Invest New Drugs. 2021 Dec;39(6):1568-1576. doi: 10.1007/s10637-021-01120-7. Epub 2021 Jun 23.

    Identifier: NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors. (ClinicalTrials.gov)

    • Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for BRCA-mutated breast cancer: A systematic review and meta-analysis.
    • Zhang M, Yu X, Wang J, Li Y, Cao L.
    • J Cancer Res Ther. 2021 Dec;17(7):1672-1678. doi: 10.4103/jcrt.jcrt_2085_21.
    • Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.
    • Kehm RD, MacInnis RJ, John EM, Liao Y, Kurian AW, Genkinger JM, Knight JA, Colonna SV, Chung WK, Milne R, Zeinomar N, Dite GS, Southey MC, Giles GG, McLachlan SA, Whitaker KD, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Phillips KA, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.
    • JNCI Cancer Spectr. 2021 Dec;5(6):pkab090. doi: 10.1093/jncics/pkab090.
    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 30.
    • Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
    • Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F.
    • Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280.
    • A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2.
    • Kitahara M, Hozumi Y, Machinaga M, Hayashi Y.
    • Case Rep Oncol. 2021 Nov 18;14(3):1645-1651. doi: 10.1159/000520148.
    • Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
    • Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG.
    • NPJ Breast Cancer. 2021 Nov 11;7(1):142. doi: 10.1038/s41523-021-00349-y.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Breast Irradiation is Well Tolerated in Carriers of a Pathogenic ATM Variant.
    • Zureick AH, Zakalik D, Rangarajan TS, Quinn TJ, Chen PY, Dilworth JT.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e227. doi: 10.1016/j.ijrobp.2021.07.780.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
    • Harvey-Jones E, Vinas Villaro G, Tutt A.
    • Cancer J. 2021 Nov-Dec 01;27(6):441-456. doi: 10.1097/PPO.0000000000000559.
    • Review
    • The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    • Pham MM, Hinchcliff E, Avila M, Westin SN.
    • Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
    • Miller RE.
    • Cancer J. 2021 Nov-Dec 01;27(6):506-510. doi: 10.1097/PPO.0000000000000565.
    • Review
    • Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
    • Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV.
    • Br J Cancer. 2021 Nov;125(10):1388-1398. doi: 10.1038/s41416-021-01514-7. Epub 2021 Aug 7.
    • BRCA1/BRCA2 variants of uncertain significance in clinical practice: A case report.
    • Huszno J, Piglowski W, Mazur M, Pamula-Pilat J, Zajkowicz A, Kierzkowska AF, Wojciechowska MO.
    • Mol Clin Oncol. 2021 Nov;15(5):222. doi: 10.3892/mco.2021.2385. Epub 2021 Aug 31.
    • BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
    • Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.
    • Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871.
    • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
    • Li Y, Zhan Z, Yin X, Fu S, Deng X.
    • Front Oncol. 2021 Oct 28;11:731535. doi: 10.3389/fonc.2021.731535.
    • Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    • Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, Zheng H.
    • Front Oncol. 2021 Oct 28;11:742139. doi: 10.3389/fonc.2021.742139.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    • Mehta P, Bothra SJ.
    • Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23.
    • Review. Book chapter
    • Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance.
    • Singh DD, Parveen A, Yadav DK.
    • Biomedicines. 2021 Oct 21;9(11):1512. doi: 10.3390/biomedicines9111512.
    • Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
    • Kim JY, Oh JM, Park YH, Ahn JS, Im YH.
    • Front Oncol. 2021 Oct 21;11:759150. doi: 10.3389/fonc.2021.759150.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
    • Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A.
    • Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198.
    • Prognostic difficulties of men with breast cancer.
    • Fentiman IS.
    • Breast J. 2021 Oct 15. doi: 10.1111/tbj.14297. Epub ahead of print.
    • Review
    • The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    • Greer AC, Lanes A, Poorvu PD, Kennedy P, Thomas AM, Partridge AH, Ginsburg ES.
    • Cancer. 2021 Oct 15;127(20):3872-3880. doi: 10.1002/cncr.33601. Epub 2021 Jun 23.
    • Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer.
    • Özdemir S, Silan F, Akgün MY, Araci N, Çirpan I, Koç Öztürk F, Özdemir Ö.
    • Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):158-168. doi: 10.4274/mirt.galenos.2021.82584.
    • De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.
    • Conte B, Soldato D, Razeti MG, Fregatti P, de Azambuja E, Schettini F, Prat A, Del Mastro L, Lambertini M.
    • Clin Breast Cancer. 2021 Oct 8:S1526-8209(21)00292-5. doi: 10.1016/j.clbc.2021.10.001. Epub ahead of print.
    • Review
    • Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    • Nozawa K, Yoshimura A, Iwata H.
    • N Engl J Med. 2021 Oct 7;385(15):1439. doi: 10.1056/NEJMc2112373.
    • Letter, Comment

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    • Hoshi A, Bando H, Sekine I.
    • N Engl J Med. 2021 Oct 7;385(15):1439-1440. doi: 10.1056/NEJMc2112373.
    • Letter, Comment

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India.
    • Bajpai J, Ventrapati P, Joshi S, Wadasadawala T, Rath S, Pathak R, Nandhana R, Mohanty S, Chougle Q, Engineer M, Abraham N, Ghosh J, Nair N, Gulia S, Popat P, A P, Sheth T, Desai S, Thakur M, Rangrajan V, Parmar V, Sarin R, Gupta S, Badwe RA.
    • Breast. 2021 Oct 6;60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub ahead of print.
    • Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.
    • Escala-Garcia M, Canisius S, Keeman R, Beesley J, Anton-Culver H, Arndt V, Augustinsson A, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bojesen SE, Bolla MK, Brenner H, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Couch FJ, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Easton DF, Ekici AB, Eliassen AH, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Geisler J, Giles GG, Grip M, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hartikainen JM, Heemskerk-Gerritsen BAM, Hollestelle A, Hoppe R, Hopper JL, Hunter DJ, Jacot W, Jakubowska A, John EM, Jung AY, Kaaks R, Khusnutdinova E, Koppert LB, Kraft P, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Margolin S, Mavroudis D, Muranen TA, Nevanlinna H, Olshan AF, Olsson H, Park-Simon TW, Patel AV, Peterlongo P, Pharoah PDP, Punie K, Radice P, Rennert G, Rennert HS, Romero A, Roylance R, Rüdiger T, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schoemaker MJ, Scott C, Southey MC, Surowy H, Swerdlow AJ, Tamimi RM, Teras LR, Thomas E, Tomlinson I, Troester MA, Vachon CM, Wang Q, Winqvist R, Wolk A, Ziogas A; kConFab/AOCS Investigators, Michailidou K, Chenevix-Trench G, Bachelot T, Schmidt MK.
    • Sci Rep. 2021 Oct 5;11(1):19787. doi: 10.1038/s41598-021-99409-3.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation.
    • Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
    • Int J Radiat Oncol Biol Phys. 2021 Oct 2:S0360-3016(21)02837-6. doi: 10.1016/j.ijrobp.2021.09.033. Epub ahead of print.
    • Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
    • Chang XF, Ren XL, Yang JQ, Shi JJ, Bai JH, Cui MS, Dong WW.
    • Breast. 2021 Oct;59:44-50. doi: 10.1016/j.breast.2021.05.009. Epub 2021 May 27.
    • Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    • Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB.
    • Cancer Res Treat. 2021 Oct;53(4):1084-1095. doi: 10.4143/crt.2020.1381. Epub 2021 Mar 24.
    • Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    • Mahtani R, Kittaneh M, Kalinsky K, Mamounas E, Badve S, Vogel C, Lower E, Schwartzberg L, Pegram M; Breast Cancer Therapy Expert Group (BCTEG).
    • Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29.
    • Review
    • BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis.
    • Pan JN, Lei L, Ye WW, Wang XJ, Cao WM.
    • J Breast Cancer. 2021 Oct;24(5):474-480. doi: 10.4048/jbc.2021.24.e39. Epub 2021 Sep 7.
    • Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    • Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X.
    • J Cancer Res Clin Oncol. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13.
    • Identification of metabolism-associated molecular subtype in ovarian cancer.
    • Liu X, Wu A, Wang X, Liu Y, Xu Y, Liu G, Liu L.
    • J Cell Mol Med. 2021 Oct;25(20):9617-9626. doi: 10.1111/jcmm.16907. Epub 2021 Sep 15.
    • Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.
    • Venetis K, Fusco N, Sajjadi E.
    • Front Oncol. 2021 Sep 29;11:735476. doi: 10.3389/fonc.2021.735476.

    Original research:

    Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.

    • Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
    • Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.
    • Breast radiotherapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing.
    • Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.
    • Int J Radiat Oncol Biol Phys. 2021 Sep 25:S0360-3016(21)02830-3. doi: 10.1016/j.ijrobp.2021.09.026. Epub ahead of print.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Hereditary Breast and Ovarian Cancer Screening Syndrome Profile in Women Diagnosed with Breast Cancer from Paraná State Southwest.
    • Moura JB, Ghedin CC, Takakura ÉT, Scandolara TB, Rech D, Panis C.
    • Rev Bras Ginecol Obstet. 2021 Aug;43(8):616-621. English. doi: 10.1055/s-0041-1733998. Epub 2021 Sep 21.
    • Oncoplastic Mammoplasty with disguised geometric compensation.
    • Paulinelli RR, Ribeiro LFJ, Santos TD, Caires EMS, Pontes MGM, Faria BM, Luz MV, Faria SFC, Freitas-Junior R.
    • Surg Oncol. 2021 Sep 20;39:101660. doi: 10.1016/j.suronc.2021.101660. Epub ahead of print.
    • Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status.
    • Sung H, Freedman RA, Siegel RL, Hyun N, DeSantis CE, Ruddy KJ, Jemal A.
    • Cancer. 2021 Sep 15;127(18):3310-3324. doi: 10.1002/cncr.33602. Epub 2021 May 18.
    • Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations.
    • Reichl F, Muhr D, Rebhan K, Kramer G, Shariat SF, Singer CF, Tan YY.
    • J Pers Med. 2021 Sep 15;11(9):917. doi: 10.3390/jpm11090917.
    • miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
    • Wang W, Zhang W, Wu J, Zhou Z, Ma J.
    • Clin Exp Med. 2021 Sep 14. doi: 10.1007/s10238-021-00757-1. Epub ahead of print.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer.
    • Huang KL, Liu YL, Hsu YY, Kuo WL.
    • Healthcare (Basel). 2021 Sep 13;9(9):1203. doi: 10.3390/healthcare9091203.
    • Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    • Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang KL.
    • Cancers (Basel). 2021 Sep 12;13(18):4572. doi: 10.3390/cancers13184572.
    • Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
    • Bruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, Rüland A, Kostara A, Chiari O, Dittmer-Grabowski C, Reinisch M.
    • Cancers (Basel). 2021 Sep 11;13(18):4564. doi: 10.3390/cancers13184564.
    • Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
    • Tung NM, Zakalik D, Somerfield MR; Hereditary Breast Cancer Guideline Expert Panel.
    • J Clin Oncol. 2021 Sep 10;39(26):2959-2961. doi: 10.1200/JCO.21.01532. Epub 2021 Aug 3.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression.
    • Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falcó A, Van't Veer LJ, Schmidt M, Quigley DA, Børresen-Dale AL, Kristensen VN, Balmain A, Climent J.
    • NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: 10.1038/s41523-021-00329-2.
    • Clinical consequences of BRCA2 hypomorphism.
    • Castells-Roca L, Gutiérrez-Enríquez S, Bonache S, Bogliolo M, Carrasco E, Aza-Carmona M, Montalban G, Muñoz-Subirana N, Pujol R, Cruz C, Llop-Guevara A, Ramírez MJ, Saura C, Lasa A, Serra V, Diez O, Balmaña J, Surrallés J.
    • NPJ Breast Cancer. 2021 Sep 9;7(1):117. doi: 10.1038/s41523-021-00322-9.
    • Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.
    • Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L.
    • Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515.
    • Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    • Tung N, Desai N.
    • J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761. Epub ahead of print.

    Original research:

    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    • Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.
    • Ann Oncol. 2021 Sep 6:S0923-7534(21)04458-6. doi: 10.1016/j.annonc.2021.08.2154. Epub ahead of print.
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".
    • Shraga S, Grinshpun A, Zick A, Kadouri L, Cohen Y, Maimon O, Adler-Levy Y, Zeltzer G, Granit A, Maly B, Carmon E, Meiner V, Sella T, Hamburger T, Peretz T.
    • Front Oncol. 2021 Sep 2;11:683656. doi: 10.3389/fonc.2021.683656.
    • Ultrasound Imaging Morphology is Associated with Biological Behavior in Invasive Ductal Carcinoma of the Breast.
    • Vijayaraghavan GR, Kona M, Maheswaran A, Kandil DH, Toke MK, Vedantham S.
    • J Clin Imaging Sci. 2021 Sep 2;11:48. doi: 10.25259/JCIS_60_2021.
    • Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
    • Altundag K.
    • J BUON. 2021 Sep-Oct;26(5):2202.

    Original research:

    Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

    • [A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].
    • Soyama M, Kunihisa T, Shimada N, Suzuki H, Ookawa Y, Okamoto A, Yamamoto M, Miki M, Mizumoto S, Baba M, Tanino H.
    • Gan To Kagaku Ryoho. 2021 Sep;48(9):1153-1155. Japanese.
    • Case report. [Article in Japanese]
    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
    • Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ.
    • Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7.
    • Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.
    • Davidson CD, Gillis NE, Carr FE.
    • Cancers (Basel). 2021 Aug 24;13(17):4254. doi: 10.3390/cancers13174254.
    • Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.
    • Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.
    • Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.
    • Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    • Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ.
    • Breast Cancer Res Treat. 2021 Aug 20. doi: 10.1007/s10549-021-06292-7. Epub ahead of print.
    • Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis.
    • Jiang Y, Meng XY, Deng NN, Meng C, Li LH, He ZK, Wang XY, Song ZY, Cui RJ.
    • Front Oncol. 2021 Aug 20;11:718761. doi: 10.3389/fonc.2021.718761.
    • Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
    • Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV.
    • Int J Mol Sci. 2021 Aug 19;22(16):8924. doi: 10.3390/ijms22168924.
    • Heart Rate Variability-Guided Exercise During Chemotherapy in Triathlete with Stage 1 BRCA1-Mutated Breast Cancer.
    • Talbot A, McCabe M, Daly B, Gallagher D.
    • Ir Med J. 2021 Aug 19;114(7):420.
    • Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
    • Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brüning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL; NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Dörk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, García-Sáenz JA, Giles GG, Grip M, Guénel P, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubinski J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, García-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK.
    • Breast Cancer Res. 2021 Aug 18;23(1):86. doi: 10.1186/s13058-021-01450-7.
    • High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    • Zhu L, Pan JN, Qian Z, Ye WW, Wang XJ, Cao WM.
    • Breast Cancer. 2021 Aug 17. doi: 10.1007/s12282-021-01286-1. Epub ahead of print.
    • Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
    • Franchet C, Hoffmann JS, Dalenc F.
    • Cancers (Basel). 2021 Aug 17;13(16):4132. doi: 10.3390/cancers13164132.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients.
    • Song Y, Liu H.
    • BMC Womens Health. 2021 Aug 10;21(1):295. doi: 10.1186/s12905-021-01420-3.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Guardians of the Genome: BRCA2 and Its Partners.
    • Le HP, Heyer WD, Liu J.
    • Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.
    • Venous thromboembolism incidence in cancer patients with germline BRCA mutations.
    • Muñoz AJ, de Toro M, Ortega L, López C, Gutiérrez A, Juliao DS, Arregui M, Lobato N, Echavarría I, Márquez-Rodas I, Martín M.
    • Clin Transl Oncol. 2021 Aug 9. doi: 10.1007/s12094-021-02678-7. Epub ahead of print.
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • Guideline: ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 6.

    Press release: ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer. (American Society of Clinical Oncology)

    Guidelines: Management of Hereditary Breast Cancer: Rapid Recommendation Update. (American Society of Clinical Oncology)

    • The Investigation of Associations between TP53 rs1042522, BBC3 rs2032809, CCND1 rs9344, EGFR rs2227983 Polymorphisms and Breast Cancer Phenotype and Prognosis.
    • Bekampyte J, Bartnykaite A, Savukaityte A, Ugenskiene R, Korobeinikova E, Gudaitiene J, Juozaityte E.
    • Diagnostics (Basel). 2021 Aug 5;11(8):1419. doi: 10.3390/diagnostics11081419.
    • Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art.
    • Terribile DA, Mason EJ, Murando F, DI Leone A, Sanchez AM, Scardina L, Magno S, Franco A, D'Archi S, Natale M, Lucci Cordisco E, Masetti R, Franceschini G.
    • Minerva Surg. 2021 Aug 2. doi: 10.23736/S2724-5691.21.09009-2. Epub ahead of print.
    • Review
    • Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
    • Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L.
    • Gynecol Oncol. 2021 Aug;162(2):496-505. doi: 10.1016/j.ygyno.2021.05.012. Epub 2021 May 19.
    • Meta-Analysis
    • MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells.
    • Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.
    • Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.
    • Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
    • Paik HJ, Jung YJ, Kim DI, Lee S, Jung CS, Kang SK, Kim JJ, Oh SY, Joo JH, Kim HY.
    • Oncology. 2021 [Aug];99(8):499-506. doi: 10.1159/000515790. Epub 2021 Jun 7.
    • Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    • Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ Jr, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA.
    • J Clin Oncol. 2021 Jul 29:JCO2101374. doi: 10.1200/JCO.21.01374. Epub ahead of print.
    • Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    • Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS.
    • J Clin Oncol. 2021 Jul 29:JCO2101392. doi: 10.1200/JCO.21.01392. Epub ahead of print.
    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
    • Hobbs EA, Litton JK, Yap TA.
    • Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Epub ahead of print.
    • Review
    • A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    • Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM.
    • Oncol Ther. 2021 Jul 25. doi: 10.1007/s40487-021-00162-4. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
    • Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U.
    • Int J Mol Sci. 2021 Jul 23;22(15):7884. doi: 10.3390/ijms22157884.
    • How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?
    • Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, Nguyen A, Oseni T, Specht M, Coopey SB, Gadd MA, Smith BL.
    • Ann Surg Oncol. 2021 Jul 22. doi: 10.1245/s10434-021-10445-9. Epub ahead of print.
    • Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study.
    • Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt ANJ, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA.
    • Clin Cancer Res. 2021 Jul 22:clincanres.0310.2021. doi: 10.1158/1078-0432.CCR-21-0310.
    • TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.
    • Lesueur F, Eon-Marchais S, Bonnet-Boissinot S, Beauvallet J, Dondon MG, Golmard L, Rouleau E, Garrec C, Martinez M, Toulas C, Nguyen TD, Brayotel F, Crivelli L, Maugard CM, Bubien V, Sevenet N, Gesta P, Chieze-Valero S, Nambot S, Goussot V, Mari V, Popovici, Prieur F, Morin-Meschin ME, Tinat J, Lortholary A, Dreyfus H, Bidart M, Collonge-Rame MA, Mozelle-Nivoix M, Gladieff L, Giraud S, Boutry-Kryza N, Chiesa J, Denizeau P, Bignon YJ, Uhrhammer N, Cohen-Haguenauer O, Vilquin P, Mailliez A, Coupier I, Rey JM, Lacaze E, Béra O, Colas C, Coulet F, Delnatte C, Houdayer C, Lasset C, Lemonnier J, Longy M, Noguès C, Stoppa-Lyonnet D, Vaur D, Andrieu N, Caron O.
    • Cancers (Basel). 2021 Jul 21;13(15):3659. doi: 10.3390/cancers13153659.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images.
    • Wang X, Zou C, Zhang Y, Li X, Wang C, Ke F, Chen J, Wang W, Wang D, Xu X, Xie L, Zhang Y.
    • Front Genet. 2021 Jul 20;12:661109. doi: 10.3389/fgene.2021.661109.
    • Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
    • Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM.
    • Sci Rep. 2021 Jul 20;11(1):14747. doi: 10.1038/s41598-021-94195-4.
    • OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    • Davey MG, Richard V, Lowery AJ, Kerin MJ.
    • Eur J Cancer. 2021 Jul 17;154:209-216. doi: 10.1016/j.ejca.2021.06.032. Epub ahead of print.
    • Investigational Drug Treatments for Triple-Negative Breast Cancer.
    • Damaskos C, Garmpis N, Garmpi A, Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D, Antoniou EA, Karamouzis MV, Nikolettos N, Kontzoglou K, Patsouras A, Voutyritsa E, Syllaios A, Koustas E, Trakas N, Dimitroulis D.
    • J Pers Med. 2021 Jul 10;11(7):652. doi: 10.3390/jpm11070652.
    • Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
    • McCrea C, Hettle R, Gulati P, Taneja A, Rajora P.
    • J Comp Eff Res. 2021 Jul 7. doi: 10.2217/cer-2021-0097. Epub ahead of print.
    • Review
    • Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
    • Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V.
    • Eur J Cancer. 2021 Jul 6;154:35-45. doi: 10.1016/j.ejca.2021.05.037. Epub ahead of print.
    • A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.
    • Wu Y, Pan X, Dou J, Zhang Q, Li Y, Sheng Y, Liu X.
    • Clin Med Insights Oncol. 2021 Jul 2;15:11795549211028569. doi: 10.1177/11795549211028569.
    • Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
    • Gonda K, Horita S, Maejima Y, Takenoshita S, Shimomura K.
    • Sci Prog. 2021 Jul-Sep;104(3):368504211039590. doi: 10.1177/00368504211039590.
    • Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    • Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M.
    • Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25.
    • Precision medicine in breast cancer: From clinical trials to clinical practice.
    • Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G.
    • Cancer Treat Rev. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12.
    • Review
    • Ovarian metastasis from breast cancer mimicking a primary ovarian neoplasm: A case report.
    • Akizawa Y, Kanno T, Horibe Y, Shimizu Y, Noguchi E, Yamamoto T, Okamoto T, Nagashima Y, Tabata T.
    • Mol Clin Oncol. 2021 Jul;15(1):135. doi: 10.3892/mco.2021.2297. Epub 2021 May 17. PMID: 34055350; PMCID: PMC8145603.
    • Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer.
    • [No author given]
    • Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S3-S4. doi: 10.1002/onco.13863. Epub 2021 Jun 21.
    • Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    • Abubakar M, Guo C, Koka H, Zhu B, Deng J, Hu N, Zhou B, Garcia-Closas M, Lu N, Yang XR.
    • Breast Cancer Res Treat. 2021 Jun 29. doi: 10.1007/s10549-021-06294-5. Epub ahead of print.
    • Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
    • Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D.
    • Front Oncol. 2021 Jun 28;11:686776. doi: 10.3389/fonc.2021.686776.
    • An Application of the Patient Rule-Induction Method to Detect Clinically Meaningful Subgroups from Failed Phase III Clinical Trials.
    • Dyson G.
    • Int J Clin Biostat Biom. 2021;7(1):038. doi: 10.23937/2469-5831/1510038. Epub 2021 Jun 28.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J.
    • J Pers Med. 2021 Jun 28;11(7):612. doi: 10.3390/jpm11070612.
    • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    • Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators.
    • N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.

    News: 'Exciting': Olaparib Benefit Also in Early BRCA+ Breast Cancer. (Medscape)

    Press: Drug may help more women survive hereditary breast cancer. (The Guardian)

    Press: Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study Finds. (The Wall Street Journal)

    Letter, Comment:

    Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.

    Letter, Comment:

    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.

    Letter, Comment:

    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.

    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
    • Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S.
    • Diagnostics (Basel). 2021 Jun 23;11(7):E1144. doi: 10.3390/diagnostics11071144.
    • Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients.
    • AbdelHamid S, El-Mesallamy H, Aziz HA, Zekri AR.
    • Biology (Basel). 2021 Jun 22;10(7):566. doi: 10.3390/biology10070566.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    • Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.
    • Gynecol Oncol. 2021 Jun 22:S0090-8258(21)00489-3. doi: 10.1016/j.ygyno.2021.06.009. Epub ahead of print.
    • Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data.
    • Worcester S.
    • Medscape Oncology. 2021 Jun 21.

    Press Release: ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer. (ASCO)

    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer .
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Jun 17.
    • Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.
    • Wang Y, van den Broek AJ, Schmidt MK.
    • Breast Cancer Res Treat.2021 Jun 16. doi: 10.1007/s10549-021-06289-2. Epub ahead of print.
    • Letter, Comment

    Review:

    Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.

    • Relevance of Platinum-Free Interval and BRCA Reversion Mutations for Veliparib Monotherapy After Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    • Puhalla SL, Diéras V, Arun BK, Kaufman B, Wildiers H, Han HS, Ayoub JP, Stearns V, Yuan Y, Helsten T, Riley-Gillis B, Murphy E, Kundu MG, Wu M, Maag D, Ratajczak CK, Ramathal CY, Friedlander M.
    • Clin Cancer Res. 2021 Jun 15:clincanres.0748.2021. doi: 10.1158/1078-0432.CCR-21-0748. Epub ahead of print.
    • Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer.
    • Miller KD.
    • Medscape Oncology. 2021 Jun 11.
    • The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
    • Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Couch FJ, Daly MB, Dennis J, Dhawan M, Domchek SM, Eeles R, Engel C, Evans DG, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Gayther SA, Gerdes AM, Godwin AK, Goldgar DE, Hahnen E, Hake CR, Hamann U, Hogervorst FBL, Hooning MJ, Hopper JL, Hulick PJ, Imyanitov EN; OCGN Investigators; HEBON Investigators; KconFab Investigators, Isaacs C, Izatt L, Jakubowska A, James PA, Janavicius R, Jensen UB, Jiao Y, John EM, Joseph V, Karlan BY, Kets CM, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud JT, Lubinski J, Manoukian S, McGuffog L, Miller A, Gomes DM, Montagna M, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Olah E, Olopade OI, Park SK, Parsons MT, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch HA, Schmutzler RK, Sharma P, Simard J, Singer CF, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Wappenschmidt B, Devilee P, van Asperen CJ, Bernstein JL, Offit K, Easton DF, Rookus MA, Chenevix-Trench G, Antoniou AC, Robson M, Schmidt MK.
    • Genet Med. 2021 Jun 10. doi: 10.1038/s41436-021-01198-7. Epub ahead of print.
    • Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA.
    • Ann Oncol. 2021 Jun 8:S0923-7534(21)02047-0. doi: 10.1016/j.annonc.2021.06.002. Epub ahead of print.
    • Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion.
    • Hopkins C.
    • GenomeWeb. Disease Areas. Cancer. 2021 Jun 7.
    • News
    • Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations.
    • Kim KH, Kim HS, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB, Chang JS.
    • Cancer Res Treat. 2021 Jun 4. doi: 10.4143/crt.2020.1247. Epub ahead of print.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    • Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators.
    • Eur J Cancer. 2021 Jun 1;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub ahead of print.
    • Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Wunderle M, Häberle L, Hein A, Jud SM, Lux MP, Hack CC, Emons J, Heindl F, Nabieva N, Loehberg CR, Schulz-Wendtland R, Hartmann A, Beckmann MW, Fasching PA, Gass P.
    • Breast Care (Basel). 2021 Jun;16(3):254-262. doi: 10.1159/000507475. Epub 2020 Jul 1.
    • PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
    • Yan F, Jiang Q, He M, Shen P.
    • Future Oncol. 2021 Jun;17(18):2381-2393. doi: 10.2217/fon-2020-1175. Epub 2021 Mar 31.
    • Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2021 Jun;161(3):653-659. doi: 10.1016/j.ygyno.2021.03.011. Epub 2021 Mar 15.
    • Landmark trials in the medical oncology management of metastatic breast cancer.
    • Lu P, Santa-Maria CA, Ballinger TJ, Sheng JY.
    • Semin Oncol. 2021 Jun;48(3):246-258. doi: 10.1053/j.seminoncol.2021.06.003. Epub 2021 Jul 16.
    • Review
    • Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
    • Sakibuzzaman M, Mahmud S, Afroze T, Fathma S, Zakia UB, Afroz S, Zafar F, Hossain M, Barua A, Akter S, Chowdhury HI, Ahsan E, Eshan SH, Fariza TT.
    • Int J Neurosci. 2021 May 27:1-18. doi: 10.1080/00207454.2021.1935929. Epub ahead of print.
    • Review
    • Breast Cancer Predisposition Genes and Synthetic Lethality.
    • Neiger HE, Siegler EL, Shi Y.
    • Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
    • Fasching PA, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, Polley EC, Lee KY, Gnanaolivu RD, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux MP, Ekici AB, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg HC, Beckmann MW, Reis A, Hartmann A, Janni W, Wimberger P, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD, Couch FJ.
    • J Clin Oncol. 2021 May 20;39(15):1619-1630. doi: 10.1200/JCO.20.01200. Epub 2021 Mar 29.
    • A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    • Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K.
    • Cancers (Basel). 2021 May 16;13(10):2401. doi: 10.3390/cancers13102401.
    • Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 May 15;81(10):2774-2787. doi: 10.1158/0008-5472.CAN-20-2912. Epub 2021 Jan 29.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice.
    • Stucci LS, Internò V, Tucci M, Perrone M, Mannavola F, Palmirotta R, Porta C.
    • Genes (Basel). 2021 May 13;12(5):727. doi: 10.3390/genes12050727.
    • Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
    • Nagayama A, Vidula N, Bardia A.
    • Oncology (Williston Park). 2021 May 13;35(5):249-254. doi: 10.46883/ONC.2021.3505.0249.
    • Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
    • Lazzari G, Buono G, Zannino B, Silvano G.
    • Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075.
    • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    • Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H.
    • Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
    • Li C, Li X.
    • Onco Targets Ther. 2021 May 3;14:2929-2939. doi: 10.2147/OTT.S298720.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.
    • Sourouni M, Kiesel L.
    • Geburtshilfe Frauenheilkd. 2021 May;81(5):549-554. doi: 10.1055/a-1390-4353. Epub 2021 May 20.
    • An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
    • Cortesi L, Rugo HS, Jackisch C.
    • Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4. Epub 2021 Mar 12.
    • CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects.
    • Apostolou P, Dellatola V, Papadimitriou C, Kalfakakou D, Fountzilas E, Faliakou E, Fountzilas G, Romanidou O, Konstantopoulou I, Fostira F.
    • Cancers (Basel). 2021 Apr 27;13(9):2106. doi: 10.3390/cancers13092106.
    • Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
    • Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A.
    • Cancers (Basel). 2021 Apr 27;13(9):2117. doi: 10.3390/cancers13092117.
    • Congenital bilateral cryptorchidism in an infant conceived after maternal breast cancer treatment: A case report.
    • Hu WK, Liu J, Liu RX, Liu XW, Yin CH.
    • World J Clin Cases. 2021 Apr 26;9(12):2923-2929. doi: 10.12998/wjcc.v9.i12.2923.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.
    • Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H.
    • J Clin Pharmacol. 2021 Apr 24. doi: 10.1002/jcph.1875. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    • Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.
    • Cochrane Database Syst Rev. 2021 Apr 22;4:CD011395. doi: 10.1002/14651858.CD011395.pub2.
    • Review
    • Comments on "Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns".
    • Brane A, Behring M, Halilova KI, Norian L.
    • Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33605. Epub ahead of print.
    • Letter, Commentary

    Original research:

    Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns.

    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
    • Wu R, Adachi K, Koyama Y, Orimoto K, Okazaki M, Asaoka M, Teraoka S, Ueda A, Miyahara K, Kawate T, Kaise H, Yamada K, Sato E, Ishikawa T.
    • J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018.
    • Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.
    • Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H.
    • Sci Rep. 2021 Apr 14;11(1):8109. doi: 10.1038/s41598-021-87645-6.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • Research advances and new challenges in overcoming triple-negative breast cancer.
    • Zong Y, Pegram M.
    • Cancer Drug Resist. 2021;4(3):517-542. doi: 10.20517/cdr.2021.04. Epub 2021 Apr 8.
    • An overview on breast cancer genetics and recent innovations: Literature survey.
    • Ramya Sree PR, Thoppil JE.
    • Breast Dis. 2021 Apr 7. doi: 10.3233/BD-201040. Epub ahead of print.
    • Review
    • Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort.
    • Aristarco V, Johansson H, Gandini S, Macis D, Zanzottera C, Tolva G, Feroce I, Accornero C, Bonanni B, Guerrieri-Gonzaga A, Serrano D.
    • Nutrients. 2021 Apr 6;13(4):1208. doi: 10.3390/nu13041208.
    • Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
    • Schwartzberg LS, Kiedrowski LA.
    • Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962.
    • Synthetic Lethality in Cancer Therapeutics: The Next Generation.
    • Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN.
    • Cancer Discov. 2021 Apr 1. doi: 10.1158/2159-8290.CD-20-1503. Epub ahead of print.
    • Review
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
    • Fresa A, Sica S.
    • Hered Cancer Clin Pract. 2021 Apr 1;19(1):22. doi: 10.1186/s13053-021-00179-w.
    • Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    • Wan Q, Su L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • JAMA Netw Open. 2021 Apr 1;4(4):e216259. doi: 10.1001/jamanetworkopen.2021.6259.

    Commentary:

    Mastectomy or Breast-Conserving Therapy for BRCA1/2 Variant Carriers.

    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years.
    • Chaudhary LN.
    • JCO Oncol Pract. 2021 Apr 1:OP2100111. doi: 10.1200/OP.21.00111. Epub ahead of print.
    • Breast cancer.
    • Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G.
    • Lancet. 2021 Apr 1:S0140-6736(20)32381-3. doi: 10.1016/S0140-6736(20)32381-3. Epub ahead of print.
    • Review
    • Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
    • Davey MG, Davey CM, Ryan ÉJ, Lowery AJ, Kerin MJ.
    • Breast. 2021 Apr;56:26-34. doi: 10.1016/j.breast.2021.02.001. Epub 2021 Feb 4.
    • Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
    • Liu M, Xie F, Liu M, Zhang Y, Wang S.
    • Breast Cancer Res Treat. 2021 Apr;186(3):591-605. doi: 10.1007/s10549-021-06104-y. Epub 2021 Feb 9.
    • Review

    Letter, Comment:

    Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.

    • Delayed unilateral hematoma after reconstructive and aesthetic breast surgery with implants in Asian patients: two case reports.
    • Lee JH, Hong HK, Kim WH, Kim HJ, Lee J, Park HY, Yang JD, Lee JS.
    • Gland Surg. 2021 Apr;10(4):1515-1522. doi: 10.21037/gs-20-854.
    • Bilateral nipple-sparing mastectomy and breast reconstruction in BRCA1 mutation-positive simultaneous bilateral breast cancer: A case study.
    • Yoneyama K, Nakagawa M, Hara A.
    • Int J Surg Case Rep. 2021 Apr;81:105788. doi: 10.1016/j.ijscr.2021.105788. Epub 2021 Mar 17.
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
    • Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O, Petrakova K, Svoboda M, Poprach A.
    • Cancers (Basel). 2021 Mar 30;13(7):1586. doi: 10.3390/cancers13071586.
    • Understanding Breast Implant Risks.
    • Spittal K.
    • FORCE. XRAY. 2021 Mar 30.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
    • Cortesi L, Piombino C, Toss A.
    • J Pers Med. 2021 Mar 28;11(4):245. doi: 10.3390/jpm11040245.

    Original research:

    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

    Original research:

    Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.

    • Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
    • Schick J, Ritchie RP, Restini C.
    • Breast Cancer (Auckl). 2021 Mar 24;15:1178223421995854. doi: 10.1177/1178223421995854.
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • Overview of recent advances in metastatic triple negative breast cancer.
    • O'Reilly D, Sendi MA, Kelly CM.
    • World J Clin Oncol. 2021 Mar 24;12(3):164-182. doi: 10.5306/wjco.v12.i3.164.
    • Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    • Cipriano É, Mesquita A.
    • Breast Cancer (Auckl). 2021 Mar 22;15:11782234211002491. doi: 10.1177/11782234211002491.
    • Role of Platinums in Triple-Negative Breast Cancer.
    • Lynce F, Nunes R.
    • Curr Oncol Rep. 2021 Mar 22;23(5):50. doi: 10.1007/s11912-021-01041-x.
    • Review
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.
    • The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
    • Ruscito I, Gasparri ML, De Marco MP, Costanzi F, Besharat AR, Papadia A, Kuehn T, Gentilini OD, Bellati F, Caserta D.
    • Cancers (Basel). 2021 Mar 19;13(6):1391. doi: 10.3390/cancers13061391.
    • PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
    • Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, He S.
    • Aging (Albany NY). 2021 Mar 11;13(6):8975-8988. doi: 10.18632/aging.202724. Epub 2021 Mar 11.
    • Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
    • Chen X, Gao Y, Zhang G, Li B, Ma T, Ma Y, Wang X.
    • J Cancer. 2021 Mar 5;12(9):2643-2653. doi: 10.7150/jca.53303.
    • Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.
    • Ren XY, Song Y, Wang J, Chen LY, Pang JY, Zhou LR, Shen SJ, Cao X, Wang YX, Shao MM, Liang ZY, Sun Q, Wu HW.
    • Front Oncol. 2021 Mar 4;11:570623. doi: 10.3389/fonc.2021.570623.

    Commentary:

    Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.

    • Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives.
    • Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S, Suto A.
    • Cancers (Basel). 2021 Mar 3;13(5):1078. doi: 10.3390/cancers13051078.
    • Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
    • Oh SY, Rahman S, Sparano JA.
    • Expert Opin Pharmacother. 2021 Mar 1. doi: 10.1080/14656566.2021.1876662. Epub ahead of print.
    • Review
    • [The Treatment of Olaparib for BRCA Positive-Metastatic Breast Cancer Patient].
    • Yamamoto D, Yamamoto C, Okugawa H, Tsubota Y, Kawakami K.
    • Gan To Kagaku Ryoho. 2021 Mar;48(3):455-456. Japanese.
    • Case report, [Article in Japanese]
    • The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    • Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y.
    • Clin Med Insights Oncol. 2021 Feb 25;15:1179554921996288. doi: 10.1177/1179554921996288.
    • Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse.
    • Sorrells S, McKinnon KE, McBratney A, Sumey C.
    • NPJ Genom Med. 2021 Feb 22;6(1):17. doi: 10.1038/s41525-021-00181-0.
    • Survival from breast cancer in women with a BRCA2 mutation by treatment.
    • Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, Lubinski J, Huzarski T, Hyder Z, Forde C, Metcalfe K, Senter L, Weitzel J, Tung N, Zakalik D, Ekholm M, Sun P, Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2021 Feb 18. doi: 10.1038/s41416-020-01164-1. Epub ahead of print.
    • Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns.
    • Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Borg Å, Vallon-Christersson J, Hall P, Czene K.
    • Int J Cancer. 2021 Feb 15;148(4):884-894. doi: 10.1002/ijc.33270. Epub 2020 Sep 5.

    Letter, Commentary:

    Comments on "Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns".

    • Clinicopathological Correlates of ?d T Cell Infiltration in Triple-Negative Breast Cancer.
    • Boissière-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J, Bonnefoy N, Lafont V, Jacot W.
    • Cancers (Basel). 2021 Feb 12;13(4):765. doi: 10.3390/cancers13040765.
    • Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.
    • Lambertini M, Ceppi M, Hamy AS, Caron O, Poorvu PD, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Duhoux FP, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Ferreira AR, Partridge AH, Di Meglio A, Saule C, Peccatori FA, Bruzzone M, t'Kint de Roodenbeke MD, Ameye L, Balmaña J, Del Mastro L, Azim HA Jr.
    • NPJ Breast Cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w.
    • Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    • Kanana N, Ben David MA, Nissan N, Yagil Y, Shalmon A, Halshtok O, Gotlieb M, Faermann R, Klang E, Samoocha D, Yassin M, Davidson T, Zippel D, Madorsky Feldman D, Friedman E, Kaidar-Person O, Sklair Levy M.
    • Breast J. 2021 Feb 11. doi: 10.1111/tbj.14190. Epub ahead of print.
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Molecular analyses of triple-negative breast cancer in the young and elderly.
    • Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
    • Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    • Hinchcliff E, Chelariu-Raicu A, Westin SN.
    • Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678.
    • Review
    • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    • Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Duc AN, Chui SY, Husain A, Winer EP, Adams S, Schmid P.
    • J Natl Cancer Inst. 2021 Feb 1:djab004. doi: 10.1093/jnci/djab004. Epub ahead of print.
    • Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
    • Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
    • Clin Breast Cancer. 2021 Feb;21(1):47-56. doi: 10.1016/j.clbc.2020.07.003. Epub 2020 Jul 9.
    • Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    • Di Leone A, Fragomeni SM, Scardina L, Ionta L, Mulè A, Magno S, Terribile D, Masetti R, Franceschini G.
    • Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1910-1915. doi: 10.26355/eurrev_202102_25087.
    • Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review.
    • Lam TC.
    • J Immunother Precis Oncol. 2021 Jan 29 [eCollection 2021 Feb];4(1):16-20. doi: 10.36401/JIPO-20-24.
    • Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    • Chen Z, Wang X, Li X, Zhou Y, Chen K.
    • J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.
    • Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 Jan 29:canres.2912.2020. doi: 10.1158/0008-5472.CAN-20-2912. Epub ahead of print.
    • Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers.
    • Arakelyan A, Melkonyan A, Hakobyan S, Boyarskih U, Simonyan A, Nersisyan L, Nikoghosyan M, Filipenko M, Binder H.
    • Int J Mol Sci. 2021 Jan 28;22(3):1266. doi: 10.3390/ijms22031266.
    • Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.
    • Boujemaa M, Hamdi Y, Mejri N, Romdhane L, Ghedira K, Bouaziz H, El Benna H, Labidi S, Dallali H, Jaidane O, Ben Nasr S, Haddaoui A, Rahal K, Abdelhak S, Boussen H, Boubaker MS.
    • PLoS One. 2021 Jan 27;16(1):e0245362. doi: 10.1371/journal.pone.0245362.
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • ASCO 2020: highlights in breast cancer.
    • Bartsch R.
    • Memo. 2021 Jan 24:1-4. doi: 10.1007/s12254-021-00674-9. Epub ahead of print.
    • Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
    • Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, Coussy F, Sablin MP, Debled M, Lefeuvre-Plesse C, Goncalves A, Reynier MM, Jacot W, You B, Barthelemy P, Verret B, Isambert N, Tchiknavorian X, Levy C, Thery JC, L'Haridon T, Ferrero JM, Mege A, Del Piano F, Rouleau E, Tran-Dien A, Adam J, Lusque A, Jimenez M, Jacquet A, Garberis I, Andre F.
    • Nat Med. 2021 Jan 18. doi: 10.1038/s41591-020-01189-2. Epub ahead of print.
    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer.
    • Nehlig A, Reix N, Arbogast P, Mathelin C.
    • Eur J Nutr. 2021 Jan 13. doi: 10.1007/s00394-020-02465-0. Epub ahead of print.
    • Review
    • Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2021 Jan 11;10:574813. doi: 10.3389/fonc.2020.574813.
    • Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
    • Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J.
    • Sci Rep. 2021 Jan 8;11(1):82. doi: 10.1038/s41598-020-80081-y.
    • Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    • Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA.
    • Eur J Cancer. 2021 Jan 7;145:44-52. doi: 10.1016/j.ejca.2020.12.007. Epub ahead of print.
    • Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    • Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.
    • PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025.
    • PARPi, immunothérapies et anticorps monoclonaux conjugués dans les cancers du sein triple-négatifs [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    • Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M.
    • Bull Cancer. 2021 Jan 6:S0007-4551(20)30504-X. French. doi: 10.1016/j.bulcan.2020.11.007. Epub ahead of print.
    • Review. [Article in French]
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    • Pop L, Suciu I, Ionescu O, Bacalbasa N, Ionescu P.
    • J Med Life. 2021 Jan-Mar;14(1):17-20. doi: 10.25122/jml-2020-0132.
    • PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    • Layman RM, Arun B.
    • Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
    • Review
    • Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast.
    • Ann Oncol. 2021 Jan;32(1):49-57. doi: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21.
    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2021 Jan;32(1):58-65. doi: 10.1016/j.annonc.2020.10.475. Epub 2020 Oct 21.
    • First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    • Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS.
    • Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28.

    Commentary:

    ATR Inhibition as an Attractive Therapeutic Resource against Cancer.

    Press: Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest (Precision Oncology News)

    • Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
    • Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M.
    • Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31.
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    • Tsunoda Y, Sasaki A, Sakamoto N, Haruyama Y, Nashimoto M, Koshida Y, Fukuma E.
    • Gan To Kagaku Ryoho. 2021 Jan;48(1):53-56.
    • [Article in Japanese]
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • Integrating PARP inhibitors into the management of breast cancer: where are we?
    • Azim HA, Kassem L, Azim H Jr.
    • Chin Clin Oncol. 2020 Dec 31:cco-19-230. doi: 10.21037/cco-19-230. Epub ahead of print.
    • Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    • Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A.
    • ESMO Open. 2020 Dec 31;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub ahead of print.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
    • Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I.
    • Breast. 2020 Dec 24;55:98-104. doi: 10.1016/j.breast.2020.12.008. Epub ahead of print.
    • Surgical Treatment after Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study.
    • Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, Peppercorn J, Borges VF, Warner E, Vardeh H, Collins LC, Gaither R, King TA, Partridge AH.
    • Ann Surg. 2020 Dec 23;Publish Ahead of Print. doi: 10.1097/SLA.0000000000004296. Epub ahead of print.
    • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    • Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE.
    • J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.

    Commentary, Review:

    Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

    • In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
    • Narod SA, Giannakeas V.
    • J Clin Oncol. 2020 Dec 20;38(36):4352. doi: 10.1200/JCO.20.02253. Epub 2020 Oct 30.

    Letter, Comment:

    Reply to S. A. Narod et al.

    Original research:

    Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.

    • Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center.
    • Tasca G, Dieci MV, Baretta Z, Faggioni G, Montagna M, Nicoletto MO, Peccatori FA, Guarneri V, Colombo N.
    • Front Oncol. 2020 Dec 14;10:608783. doi: 10.3389/fonc.2020.608783.
    • Epidemiological and ES cell-based Functional Evaluation of BRCA2 Variants Identified in Families with Breast Cancer.
    • Sullivan T, Thirthagiri E, Chong CE, Stauffer S, Reid S, Southon E, Hassan T, Ravichandran A, Wijaya E, Lim J, Taib NAM, Fadzli F, Yip CH, Hartman M, Li J, van Dam RM; SGBCC Investigators; MYBRCA Investigators, North SL, Das R, Easton DF, Biswas K, Teo SH, Sharan SK.
    • Hum Mutat. 2020 Dec 13. doi: 10.1002/humu.24154. Epub ahead of print.
    • Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status.
    • Hopkins C.
    • Precision Oncology News. 2020 Dec 11.
    • Conference news
    • Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS.
    • Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681.
    • BRCAness as a prognostic indicator in patients with early breast cancer.
    • Liu L, Matsunaga Y, Tsurutani J, Akashi-Tanaka S, Masuda H, Ide Y, Hashimoto R, Inuzuka M, Watanabe C, Taruno K, Sawada T, Okuyama H, Ata A, Kuwayama T, Nakayama S, Tonouchi Y, Nakamura S.
    • Sci Rep. 2020 Dec 3;10(1):21173. doi: 10.1038/s41598-020-78016-8.
    • Biomarkers in Her2- Positive Disease.
    • Klocker EV, Suppan C.
    • Breast Care (Basel). 2020 Dec;15(6):586-593. doi: 10.1159/000512283. Epub 2020 Oct 28.
    • Novel therapies for triple-negative breast cancer.
    • Nanda R.
    • Clin Adv Hematol Oncol. 2020 Dec;18(12):799-801.
    • [A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine].
    • Sato T, Kouno T, Hirose S, Oikawa H, Machino C, Funakoshi S.
    • Gan To Kagaku Ryoho. 2020 Dec;47(13):1747-1749.
    • Case report. [Article in Japanese]
    • [Selection of Operative Procedure for Breast Cancer in Carriers of BRCA VUS in Japan].
    • Kakimoto M, Asai D, Akamine K, Kobayashi R, Yamazaki N, Morimoto Y, Kubo K, Yamada N, Kobayashi A, Ogata K, Hasegawa K.
    • Gan To Kagaku Ryoho. 2020 Dec;47(13):2092-2094.
    • [Article in Japanese]
    • Triple-negative breast cancer therapy: Current and future perspectives (Review).
    • Won KA, Spruck C.
    • Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.
    • Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.
    • Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X.
    • Aging (Albany NY). 2020 Nov 30;12. doi: 10.18632/aging.202152. Epub ahead of print.
    • Locoregional treatments and ipsilateral breast cancer recurrence rates in BRCA1/2 mutation carriers.
    • Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Gal-Yam EN, Kaufman B, Friedman E, Kaidar-Person O.
    • Int J Radiat Oncol Biol Phys. 2020 Nov 28:S0360-3016(20)34598-3. doi: 10.1016/j.ijrobp.2020.11.058. Epub ahead of print.
    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.
    • Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
    • Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F.
    • Genes (Basel). 2020 Nov 19;11(11):E1367. doi: 10.3390/genes11111367.
    • Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    • Nagaraj G, Ma CX.
    • Adv Ther. 2020 Nov 15. doi: 10.1007/s12325-020-01552-2. Epub ahead of print.
    • A review of current progress in triple-negative breast cancer therapy.
    • Shen M, Pan H, Chen Y, Xu YH, Yang W, Wu Z.
    • Open Med (Wars). 2020 Nov 14;15(1):1143-1149. doi: 10.1515/med-2020-0138.
    • Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.
    • Palleschi M, Iaia ML, Casadei C.
    • Breast Cancer Res Treat. 2020 Nov 10. doi: 10.1007/s10549-020-06010-9. Epub ahead of print.
    • Letter

    Original research:

    Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

    • Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.
    • Wang CJ, Xu Y, Lin Y, Zhu HJ, Zhou YD, Mao F, Zhang XH, Huang X, Zhong Y, Sun Q, Li CG.
    • Front Oncol. 2020 Nov 9;10:592998. doi: 10.3389/fonc.2020.592998.
    • Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    • Grinda T, Delaloge S.
    • Ann Oncol. 2020 Nov;31(11):1432-1434. doi: 10.1016/j.annonc.2020.09.018. Epub 2020 Sep 29.

    Original research:

    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

    • Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    • Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J.
    • Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20.

    Editorial:

    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?

    Commentary:

    PARP inhibitors coming of age.

    • Nipple-sparing mastectomy: A review of outcomes at a single institution.
    • Woodward S, Willis A, Lazar M, Berger AC, Tsangaris T.
    • Breast J. 2020 Nov;26(11):2183-2187. doi: 10.1111/tbj.14088. Epub 2020 Nov 2.
    • Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
    • Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.
    • Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
    • Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer.
    • Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q.
    • Front Oncol. 2020 Oct 30;10:583314. doi: 10.3389/fonc.2020.583314. PMID: 33194720; PMCID: PMC7662137.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review
    • Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
    • Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J.
    • BMC Cancer. 2020 Oct 14;20(1):994. doi: 10.1186/s12885-020-07481-1.
    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.
    • Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
    • Yoshimura A, Yokoyama S, Iwata H, Takaiso N, Nomizu T, Arai M, Nakamura S.
    • J Hum Genet. 2020 Oct 9. doi: 10.1038/s10038-020-00850-5. Epub ahead of print.
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
    • Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.
    • Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5.
    • Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans.
    • Kim H, Choi DH, Park W.
    • Medicina (Kaunas). 2020 Oct 1;56(10):E514. doi: 10.3390/medicina56100514.
    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct;86(10):1243-1247. doi: 10.1177/0003134820964208. Epub 2020 Oct 26.
    • Male Breast Cancer: 13-Year Single Institution Experience.
    • Srour MK, Amersi F, Mirocha J, Giuliano AE, Chung A.
    • Am Surg. 2020 Oct;86(10):1345-1350. doi: 10.1177/0003134820964444. Epub 2020 Oct 25.
    • Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    • Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH.
    • Breast Cancer Res Treat. 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2. Epub 2020 Jul 26.
    • Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction.
    • Klapdor R, Weiß C, Kuehnle E, Kohls F, von Ehr J, Philippeit A, Hille-Betz U.
    • Breast Care (Basel). 2020 Oct;15(5):519-526. doi: 10.1159/000505449. Epub 2020 Jan 24.
    • Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer.
    • Dülgar Ö, Ilvan S, Turna ZH.
    • Eur J Breast Health. 2020 Apr 17 [eCollection 2020 Oct];16(4):276-281. doi: 10.5152/ejbh.2020.5305.
    • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK.
    • Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27.

    Commentary:

    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

    Commentary:

    PARP inhibitors coming of age.

    • Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.
    • Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubinski J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK.
    • Am J Hum Genet. 2020 Sep 28:S0002-9297(20)30321-9. doi: 10.1016/j.ajhg.2020.09.001. Epub ahead of print.
    • Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.
    • JNCI Cancer Spectr. 2020 Sep 18;5(1):pkaa083. doi: 10.1093/jncics/pkaa083.
    • Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
    • Olafsdottir EJ, Borg A, Jensen MB, Gerdes AM, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm AV, Hansen TVO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L.
    • Br J Cancer. 2020 Sep 17. doi: 10.1038/s41416-020-01056-4. Epub ahead of print.
    • Concordance of tumour characteristics and survival clustering among pairs of first-degree relatives with breast cancer.
    • Rapiti E, Tille JC, Fournier E, Saiji E, Weintraub D, Bouzourene H, Viassolo V, Bouchardy C, Chappuis PO, Benhamou S.
    • Swiss Med Wkly. 2020 Sep 14;150:w20327. doi: 10.4414/smw.2020.20327.
    • Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.
    • Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr.
    • J Clin Oncol. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. Epub 2020 Jul 16.

    Letter, Commentary:

    In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".

    Letter, Commentary:

    Reply to S. A. Narod et al.

    • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
    • Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB; kConFab Investigators, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ; HEBON Investigators, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN; SWE-BRCA Investigators, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H.
    • NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6.
    • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
    • Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R.
    • Mol Oncol. 2020 Sep 3. doi: 10.1002/1878-0261.12791. Epub ahead of print.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.
    • Huang X, Liu JQ, Zhou YD, Xu Y, Chen C, Wang X, Cao X, Yao R, Sun Q.
    • Ann Transl Med. 2020 Sep;8(18):1183. doi: 10.21037/atm-20-5996.
    • Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    • Borrie AE, Rose FA, Choi YH, Perera FE, Read N, Sexton T, Lock M, Vandenberg TA, Hahn K, Younus J, Logan D, Potvin K, Yaremko B, Yu E, Lenehan J, Welch S, Teft WA, Kim RB.
    • Breast Cancer Res Treat. 2020 Sep;183(2):365-372. doi: 10.1007/s10549-020-05777-1. Epub 2020 Jul 6.
    • [Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
    • Suzuki H, Oshino T, Hagio K, Takeshita T, Yamashita H.
    • Gan To Kagaku Ryoho. 2020 Sep;47(9):1351-1353. Japanese.
    • Case report. [Article in Japanese]
    • Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    • Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B.
    • Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.

    Comment, Letter:

    Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.

    • Nipple-sparing mastectomy with immediate breast reconstruction - early complications and outcomes of the treatment.
    • Bocian A, Kedzierawski P, Kurczych K, Jasnowski P, Maliszewski D, Kolacinska A.
    • Prz Menopauzalny. 2020 Sep;19(3):117-122. doi: 10.5114/pm.2020.99618. Epub 2020 Oct 2.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer.
    • Tacar SY, Bozgeyik E, Seber ES, Yetisyigit T, Tozkir H, Avci O, Arslan A.
    • Life Sci. 2020 Aug 23:118334. doi: 10.1016/j.lfs.2020.118334. Epub ahead of print.
    • Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    • Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.
    • JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.2965. Epub ahead of print.
    • Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
    • Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P.
    • Front Oncol. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415.
    • Basket Trial Data Supports Further Study of Lynparza, Imfinzi Regimen in BRCA-Mutated Breast Cancer.
    • Ray T.
    • Precision Oncology News. 2020 Aug 12.
    • Research news
    • Evidence for Increased Susceptibility for Breast Cancer from Exposure to Ionizing Radiation Due to Familial Breast Cancer History: Results from the Swedish Hemangioma Cohort.
    • Eidemüller M, Holmberg E, Lundell M, Karlsson P.
    • Am J Epidemiol. 2020 Jul 31:kwaa163. doi: 10.1093/aje/kwaa163. Epub ahead of print.
    • PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
    • Zhang M, Zhang J.
    • Biosci Rep. 2020 Jul 30:BSR20201648. doi: 10.1042/BSR20201648. Epub ahead of print.
    • Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
    • Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.
    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.
    • Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
    • Peleg Hasson S, Menes T, Sonnenblick A.
    • Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts.
    • Di Raimo T, Angelini F.
    • J Clin Med. 2020 Jul 25;9(8):E2377. doi: 10.3390/jcm9082377.
    • Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
    • Kuemmel S, Harrach H, Schmutzler RK, Kostara A, Ziegler-Löhr K, Dyson MH, Chiari O, Reinisch M.
    • NPJ Breast Cancer. 2020 Jul 24;6:31. doi: 10.1038/s41523-020-00174-9.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
    • González-Martínez S, Pérez-Mies B, Carretero-Barrio I, Palacios-Berraquero ML, Perez-García J, Cortés J, Palacios J.
    • Cancers (Basel). 2020 Jul 8;12(7):E1832. doi: 10.3390/cancers12071832.
    • Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
    • Desai NV, Tung NM.
    • Breast J. 2020 Jul 6. doi: 10.1111/tbj.13972. Epub ahead of print.
    • Review
    • A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation.
    • Nguyen QD, Tavana A, Saenz Rios F, Posleman Monetto FE, Robinson AS.
    • Cureus. 2020 Jul 2;12(7):e8972. doi: 10.7759/cureus.8972.
    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    • Du F, Wang W, Wang Y, Li M, Zhu A, Wang J, Cai R, Ma F, Fan Y, Li Q, Zhang P, Todorovic V, Yuan P, Xu B.
    • Breast Cancer Res Treat. 2020 Jul;182(1):67-77. doi: 10.1007/s10549-020-05648-9. Epub 2020 May 11.
    • [A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
    • Yabe S, Iwamoto N, Inokuchi T, Nara M, Saita C, Onishi M, Goto R, Yonekura R, Ishiba T, Honda Y, Miyamoto H, Aruga T.
    • Gan To Kagaku Ryoho. 2020 Jul;47(7):1089-1092. Japanese.
    • Case report. [Article in Japanese.]
    • Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
    • Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, Laurentiis M.
    • Int J Mol Sci. 2020 Jun 27;21(13):E4579. doi: 10.3390/ijms21134579.
    • Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    • Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.
    • Clin Cancer Res. 2020 Jun 22:clincanres.0638.2020. doi: 10.1158/1078-0432.CCR-20-0638. Epub ahead of print.
    • Overall survival and related prognostic factors for familial breast cancer patients: A single institution study in Iran.
    • Yousefi Kashi AS.
    • Breast J. 2020 Jun 21. doi: 10.1111/tbj.13942. Epub ahead of print.
    • Commentary
    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.
    • Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS.
    • Cancer Discov. 2020 Jun 12:CD-20-0163. doi: 10.1158/2159-8290.CD-20-0163. Epub ahead of print.
    • Study: What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation?
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 6.

    Original research:

    Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.

    • Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
    • Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B.
    • Breast J. 2020 Jun 4. doi: 10.1111/tbj.13922. Epub ahead of print.
    • Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.
    • Qin N, Wang Z, Liu Q, Song N, Wilson CL, Ehrhardt MJ, Shelton K, Easton J, Mulder H, Kennetz D, Edmonson MN, Rusch MC, Downing JR, Hudson MM, Nichols KE, Zhang J, Robison LL, Yasui Y.
    • J Clin Oncol. 2020 Jun 4:JCO1902760. doi: 10.1200/JCO.19.02760. Epub ahead of print.

    Research news: Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type. (GenomeWeb)

    • Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    • Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
    • BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.
    • Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    • Allué Cabañuz M, Domingo Bretón M, Chóliz Ezquerro J, Arribas Del Amo MD, Güemes Sánchez AT.
    • Cir Esp. 2020 Jun 3:S0009-739X(20)30115-9. English, Spanish. doi: 10.1016/j.ciresp.2020.04.008. Epub ahead of print.
    • [Article in English, Spanish.]
    • BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
    • Meng H, Yao L, Yuan H, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Jun 1;146(11):3044-3052. doi: 10.1002/ijc.32877. Epub 2020 Feb 22.
    • Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
    • Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J.
    • Chin J Cancer Res. 2020 Jun;32(3):370-382. doi: 10.21147/j.issn.1000-9604.2020.03.08.
    • Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.
    • Mainor CB, Isaacs C.
    • Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17.
    • Review
    • Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population.
    • Huang X, Cai XY, Liu JQ, Hao WW, Zhou YD, Wang X, Xu Y, Chen C, Lin Y, Wang CJ, Song Y, Sun Q.
    • Gland Surg. 2020 Jun;9(3):775-787. doi: 10.21037/gs-20-531.
    • Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy.
    • Oliver Guillén JR, Hernando Almudi E, Molina Osorio G, Ibañez Carreras R, Font Gómez JA, Vicente Gómez I, García Mur C, Casamayor Franco MC.
    • Cir Esp. 2020 May 31:S0009-739X(20)30161-5. English, Spanish. doi: 10.1016/j.ciresp.2020.04.024. Online ahead of print.
    • [Article in English, Spanish]
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
    • Lee JS, Yost SE, Yuan Y.
    • Cancers (Basel). 2020 May 29;12(6):E1404. doi: 10.3390/cancers12061404.
    • Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    • Hirotsu Y, Schmidt-Edelkraut U, Nakagomi H, Sakamoto I, Hartenfeller M, Narang R, Soldatos TG, Kaduthanam S, Wang X, Hettich S, Brock S, Jackson DB, Omata M.
    • Int J Mol Sci. 2020 May 29;21(11):E3895. doi: 10.3390/ijms21113895.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    • Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.
    • Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    • Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1623. Epub ahead of print.
    • Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    • Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1626. Epub ahead of print.
    • The evolving management of metastatic triple negative breast cancer.
    • Malhotra MK, Emens LA.
    • Semin Oncol. 2020 May 28:S0093-7754(20)30044-0. doi: 10.1053/j.seminoncol.2020.05.005.
    • Review
    • Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    • De Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers-Heijboer HE, Boer JP, van der Hulst RR, De Jong D, van Leeuwen FE.
    • Blood. 2020 May 26:blood.2019004498. doi: 10.1182/blood.2019004498. Epub ahead of print.
    • Letter
    • Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
    • Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.
    • Comparison of mutation profile between primary phyllodes tumors of the breast and their paired local recurrences.
    • Mitus J, Adamczyk A, Majchrzyk K, Kowalik A, Rys J, Niemiec J.
    • Pol J Pathol. 2020 May 20;71(1):7-12. doi: 10.5114/pjp.2020.94899.
    • AstraZeneca's Lynparza Gives Survival Boost as Maintenance in Relapsed BRCA-Mutated Ovarian Cancer.
    • Anderson A.
    • Precision Oncology News. 2020 May 14.
    • TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
    • Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE.
    • J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25.

    Letter, Commentary:

    Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.

    • Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer.
    • Greville-Heygate SL, Maishman T, Tapper WJ, Cutress RI, Copson E, Dunning AM, Haywood L, Jones LJ, Eccles DM.
    • JCO Precis Oncol. 2020 May 4;4:PO.19.00178. doi: 10.1200/PO.19.00178.
    • Breast cancer survival following MRI detection in a high-risk screening program.
    • Hollingsworth AB, Pearce MR, Stough RG.
    • Breast J. 2020 May;26(5):991-994. doi: 10.1111/tbj.13813. Epub 2020 Mar 12.
    • Comparison of breast cancer incidence, clinicopathologic features, and risk factor prevalence in women aged 20-29 at diagnosis to those aged 30-39.
    • Limbach KE, Leon E, Pommier RF, Pommier SJ.
    • Breast J. 2020 May;26(5):1069-1070. doi: 10.1111/tbj.13783. Epub 2020 Feb 14.
    • [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
    • Yoneda H, Shimizu Y, Masuda R.
    • Gan To Kagaku Ryoho. 2020 May;47(5):815-818.
    • Case report, [Article in Japanese]
    • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    • Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
    • Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
    • Review
    • Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    • Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.
    • Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.
    • Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
    • Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN.
    • Fertil Steril. 2020 Apr 21. pii: S0015-0282(20)30036-4. doi: 10.1016/j.fertnstert.2020.01.033. [Epub ahead of print]
    • BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    • Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.
    • Breast Cancer Res Treat. 2020 Apr 20. doi: 10.1007/s10549-020-05647-w. [Epub ahead of print]
    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
    • Vitiello GAF, de Sousa Pereira N, Amarante MK, Banin-Hirata BK, Campos CZ, de Oliveira KB, Losi-Guembarovski R, Watanabe MAE.
    • J Cancer Res Clin Oncol. 2020 Apr 13. doi: 10.1007/s00432-020-03208-8. [Epub ahead of print]
    • Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    • Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK.
    • Med Oncol. 2020 Apr 10;37(5):48. doi: 10.1007/s12032-020-01371-z.
    • Case report
    • Olaparib for advanced breast cancer.
    • Griguolo G, Dieci MV, Miglietta F, Guarneri V, Conte P.
    • Future Oncol. 2020 Apr 6. doi: 10.2217/fon-2019-0689. [Epub ahead of print]
    • Review
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13.
    • Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
    • Wang N, Li K, Huang W, Kong W, Liu X, Shi W, Xie F, Jiang H, Song G, Di L, Wang Q, Yu J, Li H.
    • Chin J Cancer Res. 2020 Apr;32(2):149-162. doi: 10.21147/j.issn.1000-9604.2020.02.03.
    • Clinicopathological analysis of early-stage breast cancer patients that meet indications for BRCA1/2 genetic testing.
    • Xiang H, Xin L, Liu Q, Zhang H, Zhang S, Ye J, Cheng Y, Li T, Liu Y, Xu L.
    • Chin J Cancer Res. 2020 Apr;32(2):163-174. doi: 10.21147/j.issn.1000-9604.2020.02.04.
    • Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
    • Lüftner D, Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lux MP.
    • Geburtshilfe Frauenheilkd. 2020 Apr;80(4):391-398. doi: 10.1055/a-1111-8775. Epub 2020 Apr 21.
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.
    • Boltežar L, Gašljevic G, Novakovic S, Stegel V, Škof E.
    • Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
    • Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    • Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A.
    • Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362-6. doi: 10.1016/j.annonc.2020.03.283. [Epub ahead of print]
    • Case report
    • Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
    • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0007. [Epub ahead of print]
    • Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
    • Sadzeviciene I, Jarmalaite S, Besusparis J, Liaugaudiene O, Asadauskiene J, Brasiuniene B, Kulikiene I, Sabaliauskaite R.
    • Medicina (Kaunas). 2020 Mar 10;56(3). pii: E119. doi: 10.3390/medicina56030119.
    • Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    • Reiner AS, Robson ME, Mellemkjær L, Tischkowitz M, John EM, Lynch CF, Brooks JD, Boice JD, Knight JA, Teraoka SN, Liang X, Woods M, Shen R, Shore RE, Stram DO, Thomas DC, Malone KE, Bernstein L, Riaz N, Woodward W, Powell S, Goldgar D, Concannon P; WECARE Study Collaborative Group, Bernstein JL.
    • J Natl Cancer Inst. 2020 Mar 2. pii: djaa031. doi: 10.1093/jnci/djaa031. [Epub ahead of print]
    • PARP and PARG inhibitors in cancer treatment.
    • Slade D.
    • Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
    • BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
    • Lee A, Moon BI, Kim TH.
    • Ann Lab Med. 2020 Mar;40(2):114-121. doi: 10.3343/alm.2020.40.2.114.
    • Review

    Introductory article:

    From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer.

    • OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer.
    • Sanchez AM, Orlandi A, Franceschini G, De Lauretis F, Terribile D, Franco A, Masetti R.
    • Ann Palliat Med. 2020 Mar;9(2):510-511. doi: 10.21037/apm.2020.01.14. Epub 2020 Feb 16.
    • Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    • Criscitiello C, Curigliano G.
    • Eur J Cancer. 2020 Mar;127:236-239. doi: 10.1016/j.ejca.2019.12.004. Epub 2020 Jan 20.
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
    • Li S, He Y, Li C, Liu X, Shen Y, Wu Y, Bai N, Li Q.
    • Medicine (Baltimore). 2020 Mar;99(10):e19345. doi: 10.1097/MD.0000000000019345.
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
    • García IA, Garro C, Fernandez E, Soria G.
    • Mutat Res. 2020 Feb 25;821:111693. doi: 10.1016/j.mrfmmm.2020.111693. [Epub ahead of print]
    • Review
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    • Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    • J Surg Res. 2020 Feb 21;250:200-208. doi: 10.1016/j.jss.2019.12.040. [Epub ahead of print]
    • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    • Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N.
    • Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055-5. doi: 10.1016/j.annonc.2020.02.008. [Epub ahead of print]
    • Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
    • Askeland C, Wik E, Finne K, Birkeland E, Arnes JB, Collett K, Knutsvik G, Krüger K, Davidsen B, Aas T, Eide GE, Stefansson IM, Foulkes WD, Akslen LA.
    • Sci Rep. 2020 Feb 19;10(1):2914. doi: 10.1038/s41598-020-59728-3.
    • BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    • Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E.
    • Sci Transl Med. 2020 Feb 19;12(531). pii: eaax2625. doi: 10.1126/scitranslmed.aax2625.
    • Radiation Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.
    • Schlosser S, Rabinovitch R, Shatz Z, Galper S, Shahadi-Dromi I, Finkel S, Jacobson G, Rasco A, Friedman E, Laitman Y, Evron E, Bernstein R, Weiss I, Levy MS, Ben-David MA.
    • Int J Radiat Oncol Biol Phys. 2020 Feb 18. pii: S0360-3016(20)30219-4. doi: 10.1016/j.ijrobp.2020.02.020. [Epub ahead of print]
    • Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    • Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L.
    • Expert Opin Pharmacother. 2020 Feb 13:1-13. doi: 10.1080/14656566.2020.1724957. [Epub ahead of print]
    • Review
    • Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer.
    • Huang L, Liu Q, Lang GT, Cao AY, Shao ZM.
    • Front Oncol. 2020 Feb 11;10:27. doi: 10.3389/fonc.2020.00027. eCollection 2020.
    • Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    • Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32918. [Epub ahead of print]
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.
    • Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Evans DG.
    • Cancers (Basel). 2020 Feb 7;12(2):378. doi: 10.3390/cancers12020378.

    Research news: Study: What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation? (FORCE XRAYS)

    • Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    • Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K, Oba M, Ishikawa T.
    • J Surg Res. 2020 Feb 7;250:143-147. doi: 10.1016/j.jss.2019.12.047. [Epub ahead of print]
    • BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.
    • Tazzite A, Jouhadi H, Benider A, Nadifi S.
    • Curr Drug Targets. 2020 Feb 3. doi: 10.2174/1389450121666200203162541. [Epub ahead of print]
    • Review
    • Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    • Xiao Q, Zhou Y, Winter S, Büttner F, Schaeffeler E, Schwab M, Lauschke VM.
    • Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898. [Epub ahead of print]
    • Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis.
    • Ricci AD, Rizzo A, Novelli M, Tavolari S, Palloni A, Tober N, Abbati F, Mollica V, DE Lorenzo S, Turchetti D, DI Marco M, Brandi G.
    • Anticancer Res. 2020 Feb;40(2):597-608. doi: 10.21873/anticanres.13989.
    • Review
    • PARP inhibitors: a tsunami of indications in different malignancies.
    • Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.
    • Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.
    • Review
    • Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
    • Pogoda K, Niwinska A, Sarnowska E, Nowakowska D, Jagiello-Gruszfeld A, Siedlecki J, Nowecki Z.
    • J Oncol. 2020 Jan 27;2020:8545643. doi: 10.1155/2020/8545643. eCollection 2020.
    • BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    • Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.
    • Oncology. 2020 Jan 21:1-4. doi: 10.1159/000504965. [Epub ahead of print]
    • Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    • de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M.
    • Eur J Cancer. 2020 Jan 16. pii: S0959-8049(19)30855-X. doi: 10.1016/j.ejca.2019.12.003. [Epub ahead of print]
    • A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.
    • Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale AL, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C, Canzian F, Chang-Claude J, Chanock SJ, Chin SF, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dunn JA, Dunning AM, Dwek M, Earl HM, Eccles DM, Eliassen AH, Ellberg C, Evans DG, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Giles GG, Goldgar DE, González-Neira A, Grip M, Guénel P, Guo Q, Haiman CA, Håkansson N, Hamann U, Harrington PA, Hiller L, Hooning MJ, Hopper JL, Howell A, Huang CS, Huang G, Hunter DJ, Jakubowska A, John EM, Kaaks R, Kapoor PM, Keeman R, Kitahara CM, Koppert LB, Kraft P, Kristensen VN, Lambrechts D, Le Marchand L, Lejbkowicz F, Lindblom A, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Orr N, Peterlongo P, Petridis C, Prentice RL, Presneau N, Punie K, Ramachandran D, Rennert G, Romero A, Sachchithananthan M, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, Simard J, Sohn C, Southey MC, Swerdlow AJ, Tamimi RM, Tapper WJ, Teixeira MR, Terry MB, Thorne H, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Turnbull C, Vachon CM, van der Kolk LE, Wang Q, Winqvist R, Wolk A, Yang XR, Ziogas A, Pharoah PDP, Hall P, Wessels LFA, Chenevix-Trench G, Bader GD, Dörk T, Easton DF, Canisius S, Schmidt MK.
    • Nat Commun. 2020 Jan 16;11(1):312. doi: 10.1038/s41467-019-14100-6.
    • Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    • Ryu JM, Nam SJ, Kim SW, Lee JE, Chae BJ, Lee SK, Yu J.
    • Jpn J Clin Oncol. 2020 Jan 11. pii: hyz147. doi: 10.1093/jjco/hyz147. [Epub ahead of print]
    • Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE Jr, Sikov WM, Untch M.
    • JAMA Surg. 2020 Jan 8:e195410. doi: 10.1001/jamasurg.2019.5410. [Epub ahead of print]
    • Comparison of clinical features and oncologic outcomes between familial (non-hereditary) and hereditary breast cancer in Korean female patients.
    • Park CS, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Park JY, Park JY, Lee J.
    • Asian J Surg. 2020 Jan 7. pii: S1015-9584(19)30880-2. doi: 10.1016/j.asjsur.2019.12.001. [Epub ahead of print]
    • Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    • Ye F, Huang L, Lang G, Hu X, Di G, Shao Z, Cao A.
    • Cancer Med. 2020 Jan 7. doi: 10.1002/cam4.2836. [Epub ahead of print]
    • Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    • Cheng AS, Leung SCY, Gao D, Burugu S, Anurag M, Ellis MJ, Nielsen TO.
    • Breast Cancer Res Treat. 2020 Jan;179(1):3-10. doi: 10.1007/s10549-019-05438-y. Epub 2019 Sep 14.

    Letter, Comment:

    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.

    • BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab.
    • Lin J, Yang X, Zhao H.
    • JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.4595. [Epub ahead of print]
    • Letter, Comment

    Letter, Reply:

    BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply.

    Original research:

    Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

    Original research:

    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

    • Triple negative breast cancer: A thorough review of biomarkers.
    • da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC.
    • Crit Rev Oncol Hematol. 2019 Dec 20;145:102855. doi: 10.1016/j.critrevonc.2019.102855. [Epub ahead of print]
    • BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
    • Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.
    • JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.
    • BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
    • Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N.
    • Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6.
    • Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    • Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S.
    • Drugs. 2019 Dec 10. doi: 10.1007/s40265-019-01235-5. [Epub ahead of print]
    • Review
    • Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    • Park HS, Lee JD, Kim JY, Park S, Kim JH, Han HJ, Choi YA, Choi AR, Sohn JH, Kim SI.
    • PLoS One. 2019 Dec 10;14(12):e0225082. doi: 10.1371/journal.pone.0225082. eCollection 2019.
    • Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    • Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.
    • Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]
    • Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    • Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.
    • Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]
    • Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer.
    • Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, Park SY, Kim SW, Kim EK.
    • J Breast Cancer. 2019 Sep 30;22(4):587-598. doi: 10.4048/jbc.2019.22.e47. eCollection 2019 Dec.
    • Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    • Exman P, Mallery RM, Lin NU, Parsons HA.
    • NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
    • Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    • Ruiz de Sabando A, Urrutia Lafuente E, García-Amigot F, Alonso Sánchez A, Morales Garofalo L, Moreno S, Ardanaz E, Ramos-Arroyo MA.
    • BMC Cancer. 2019 Nov 27;19(1):1145. doi: 10.1186/s12885-019-6277-x.
    • Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    • Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J.
    • Oncologist. 2019 Nov 25. pii: theoncologist.2019-0493. doi: 10.1634/theoncologist.2019-0493. [Epub ahead of print]
    • Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    • Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MDP.
    • Fam Cancer. 2019 Nov 20. doi: 10.1007/s10689-019-00153-5. [Epub ahead of print]
    • The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
    • Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.
    • J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.
    • Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.
    • Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.
    • Breast. 2019 Nov 6;49:70-73. doi: 10.1016/j.breast.2019.10.011. [Epub ahead of print]
    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients.
    • Milanese JS, Tibiche C, Zou J, Meng Z, Nantel A, Drouin S, Marcotte R, Wang E.
    • NPJ Precis Oncol. 2019 Nov 1;3:28. doi: 10.1038/s41698-019-0100-7. eCollection 2019.

    Press: Breast Cancer Recurrence Risk Predicted by Immune-Related Germline Variants. (GenomeWeb)

    • Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy.
    • Kumeta T, Matsunuma R, Yamaguchi K, Hayami R, Tsuneizumi M.
    • Case Rep Oncol. 2019 Oct 29;12(3):814-819. doi: 10.1159/000503858. eCollection 2019 Sep-Dec.
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Functional characterization of 84 PALB2 variants of uncertain significance.
    • Wiltshire T, Ducy M, Foo TK, Hu C, Lee KY, Belur Nagaraj A, Rodrigue A, Gomes TT, Simard J, Monteiro ANA, Xia B, Carvalho MA, Masson JY, Couch FJ.
    • Genet Med. 2019 Oct 21. doi: 10.1038/s41436-019-0682-z. [Epub ahead of print]
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
    • Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W.
    • JNCI Cancer Spectr. 2019 Oct 21;4(1):pkz085. doi: 10.1093/jncics/pkz085. eCollection 2020 Feb.
    • RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    • Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    • Biochim Biophys Acta Mol Basis Dis. 2019 Oct 19:165561. doi: 10.1016/j.bbadis.2019.165561. [Epub ahead of print]
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
    • Cecener G, Takanlou LS, Takanlou MS, Egeli U, Eskiler GG, Aksoy S, Unal U, Tezcan H, Eryilmaz IE, Gokgoz MS, Tunca B, Cubukcu E, Evrensel T, Cetintas S, Tasdelen I.
    • Cancer Genet. 2019 Oct 16;240:23-32. doi: 10.1016/j.cancergen.2019.10.004. [Epub ahead of print]
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
    • Rodrigue A, Margaillan G, Torres Gomes T, Coulombe Y, Montalban G, da Costa E Silva Carvalho S, Milano L, Ducy M, De-Gregoriis G, Dellaire G, Araújo da Silva W Jr, Monteiro AN, Carvalho MA, Simard J, Masson JY.
    • Nucleic Acids Res. 2019 Oct 5. pii: gkz780. doi: 10.1093/nar/gkz780. [Epub ahead of print]
    • Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising.
    • [No author given]
    • FORCE. XRAYS. 2019 Oct 4.

    Original research:

    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

    • Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    • Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU.
    • Cancer. 2019 Oct 3. doi: 10.1002/cncr.32540. [Epub ahead of print]
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
    • Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
    • Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
    • Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.
    • Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis.
    • Slavin TP, Sun CL, Chavarri-Guerra Y, Sedrak MS, Katheria V, Castillo D, Herzog J, Dale W, Hurria A, Weitzel JN.
    • J Geriatr Oncol. 2019 Sep 28. pii: S1879-4068(19)30174-2. doi: 10.1016/j.jgo.2019.09.004. [Epub ahead of print]
    • Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    • Deng M, Chen HH, Zhu X, Luo M, Zhang K, Xu CJ, Hu KM, Cheng P, Zhou JJ, Zheng S, Chen YD.
    • Int J Cancer. 2019 Sep 15;145(6):1517-1528. doi: 10.1002/ijc.32184. Epub 2019 Feb 22.
    • Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study.
    • Evans DGR, Kallionpää RA, Clementi M, Trevisson E, Mautner VF, Howell SJ, Lewis L, Zehou O, Peltonen S, Brunello A1, Harkness EF, Wolkenstein P, Peltonen J.
    • Genet Med. 2019 Sep 9. doi: 10.1038/s41436-019-0651-6. [Epub ahead of print]
    • Is it safe for BRCA mutation carriers to become pregnant following breast cancer?
    • [No author given]
    • FORCE. XRAYS. 2019 Sep 4.
    • Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer.
    • Watt GP, Reiner AS, Smith SA, Stram DO, Capanu M, Malone KE, Lynch CF, John EM, Knight JA, Mellemkjær L, Bernstein L, Brooks JD, Woods M, Liang X, Haile RW, Riaz N, Conti DV, Robson M, Duggan D, Boice JD Jr, Shore RE, Tischkowitz M, Orlow I, Thomas DC, Concannon P, Bernstein JL.
    • JAMA Netw Open. 2019 Sep 4;2(9):e1912259. doi: 10.1001/jamanetworkopen.2019.12259.
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility.
    • Keupp K, Hampp S, Hübbel A, Maringa M, Kostezka S, Rhiem K, Waha A, Wappenschmidt B, Pujol R, Surrallés J, Schmutzler RK, Wiesmüller L, Hahnen E.
    • Mol Genet Genomic Med. 2019 Sep;7(9):e863. doi: 10.1002/mgg3.863. Epub 2019 Jul 25.
    • Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    • Nuthalapati S, Stodtmann S, Shepherd SP, Ratajczak CK, Mensing S, Menon R, Xiong H.
    • Cancer Chemother Pharmacol. 2019 Aug 29. doi: 10.1007/s00280-019-03930-2. [Epub ahead of print]
    • Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    • Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worm H1, Moulder SL, Arun BK.
    • J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

    Research news: Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising. (FORCE. XRAYS.)

    • Pregnancy-associated breast cancer in a contemporary cohort of newly diagnosed women.
    • Gooch JC, Chun J, Kaplowitz E, Guth A, Axelrod D, Shapiro R, Roses D, Schnabel F.
    • Breast J. 2019 Aug 25. doi: 10.1111/tbj.13510. [Epub ahead of print]
    • A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
    • Xu K, Shi Y, Wang X, Chen Y, Tang L, Guan X.
    • Cancer Genet. 2019 Aug 23;239:26-32. doi: 10.1016/j.cancergen.2019.08.004. [Epub ahead of print]
    • Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    • Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D5, Manousou K, Delimitsou A, Papamentzelopoulou M, Fountzilas G, Yannoukakos D, Fostira F.
    • Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30642-1. doi: 10.1016/j.clbc.2019.08.003. [Epub ahead of print]
    • Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review.
    • Co M, Liu T, Leung J, Li CH, Tse T, Wong M, Kwong A.
    • Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30661-5. doi: 10.1016/j.clbc.2019.07.014. [Epub ahead of print]
    • Review
    • Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    • Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P.
    • Eur J Cancer. 2019 Aug 22;120:20-30. doi: 10.1016/j.ejca.2019.06.023. [Epub ahead of print]
    • Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
    • Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R.
    • Clin Breast Cancer. 2019 Aug 21. pii: S1526-8209(19)30646-9. doi: 10.1016/j.clbc.2019.07.004. [Epub ahead of print]
    • Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
    • Fan Z, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.
    • Cancer Sci. 2019 Aug 20. doi: 10.1111/cas.14175. [Epub ahead of print]
    • Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
    • Yang Y, Li F, Luo X, Jia B, Zhao X, Liu B, Gao R, Yang L, Wei W, He J.
    • DNA Cell Biol. 2019 Aug 19. doi: 10.1089/dna.2019.4843. [Epub ahead of print]
    • Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
    • Militello AM, Zielli T, Boggiani D, Michiara M, Naldi N, Bortesi B, Zanelli P, Uliana V, Giuliotti S, Musolino A.
    • Front Oncol. 2019 Aug 13;9:759. doi: 10.3389/fonc.2019.00759. eCollection 2019.
    • Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population-based study.
    • Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, Terry MB, Teitelbaum SL, Neugut AI, Santella RM, Chen J, Gammon MD.
    • Cancer. 2019 Aug 12. doi: 10.1002/cncr.32364. [Epub ahead of print]
    • Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
    • West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE.
    • Cancer Med. 2019 Aug 12. doi: 10.1002/cam4.2471. [Epub ahead of print]
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    • van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.
    • Ann Surg. 2019 Aug;270(2):364-372. doi: 10.1097/SLA.0000000000002804.
    • [A CASE REPORT OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A BREAST CANCER PATIENT].
    • Ben Naftali Y, Duek OS, Ullmann Y.
    • Harefuah. 2019 Aug;158(8):503-505.
    • Case report, [Article in Hebrew]
    • Molecular characteristics of breast cancer according to clinicopathological factors.
    • Huszno J, Kolosza Z.
    • Mol Clin Oncol. 2019 Aug;11(2):192-200. doi: 10.3892/mco.2019.1869. Epub 2019 May 28.
    • In BRCA mutation carriers breast conserving surgery may not be the best choice.
    • Trimboli RM, Schiaffino S, Sardanelli F.
    • Breast Cancer Res Treat. 2019 Jul 27. doi: 10.1007/s10549-019-05373-y. [Epub ahead of print]
    • Letter, Commentary

    Original research:

    Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.

    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Update on the Feasibility and Progress on Robotic Breast Surgery.
    • Toesca A, Invento A, Massari G, Girardi A, Peradze N, Lissidini G, Sangalli C, Maisonneuve P, Manconi A, Gottardi A, Baker JL, Bottiglieri L, Naninato P, Farante G, Magnoni F, De Scalzi A, Corso G, Colleoni M, De Lorenzi F, Sacchini V, Galimberti V, Intra M, Rietjens M, Veronesi P.
    • Ann Surg Oncol. 2019 Jul 24. doi: 10.1245/s10434-019-07590-7. [Epub ahead of print]
    • CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer.
    • Frick E, Gudjonsson T, Eyfjord J, Jonasson J, Tryggvadóttir L, Stefansson O, Sigurdsson S.
    • Oncotarget. 2019 Jul 23;10(45):4664-4678. doi: 10.18632/oncotarget.27083. eCollection 2019 Jul 23.
    • Development of anthracycline-induced dilated cardiomyopathy due to mutation on LMNA gene in a breast cancer patient: a case report.
    • Kuruc JC, Durant-Archibold AA, Motta J, Rao KS, Trachtenberg B, Ramos C, Wang H, Gorenstein D, Vannberg F, Jordan K.
    • BMC Cardiovasc Disord. 2019 Jul 16;19(1):169. doi: 10.1186/s12872-019-1155-7.
    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
    • Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, Leheurteur M, Demeestere I, Di Fiore F, Perdrix A, Clatot F.
    • Front Oncol. 2019 Jul 12;9:575. doi: 10.3389/fonc.2019.00575. eCollection 2019.
    • Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
    • Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.
    • Int J Mol Sci. 2019 Jul 10;20(14). pii: E3390. doi: 10.3390/ijms20143390.
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Evidence to date: talazoparib in the treatment of breast cancer.
    • Exman P, Barroso-Sousa R, Tolaney SM.
    • Onco Targets Ther. 2019 Jul 2;12:5177-5187. doi: 10.2147/OTT.S184971. eCollection 2019.
    • Targeting DNA repair in breast cancer.
    • Paluch-Shimon S, Evron E.
    • Breast. 2019 Jul 1;47:33-42. doi: 10.1016/j.breast.2019.06.007. [Epub ahead of print]
    • Review
    • Talazoparib to treat BRCA-positive breast cancer.
    • Guney Eskiler G.
    • Drugs Today (Barc). 2019 Jul;55(7):459-467. doi: 10.1358/dot.2019.55.7.3015642.
    • Review
    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    • Aktas BY, Guner G, Guven DC, Arslan C, Dizdar O.
    • Expert Rev Anticancer Ther. 2019 Jun 10. doi: 10.1080/14737140.2019.1631162. [Epub ahead of print]
    • Review
    • Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
    • Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 7];3:1-6. doi: 10.1200/PO.19.00012.
    • [Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.]
    • Palácová M.
    • Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.
    • [Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.]
    • Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    • Cao W, Xie Y, He Y, Li J, Wang T, Fan Z, Fan T, Ouyang T.
    • Breast Cancer Res Treat. 2019 Jun;175(3):749-754. doi: 10.1007/s10549-019-05199-8. Epub 2019 Mar 20.

    Letter, Commentary:

    In BRCA mutation carriers breast conserving surgery may not be the best choice.

    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • Molecular comparison of interval and screen-detected breast cancers.
    • Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.
    • J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.
    • Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, Krizova L, Kotlas J, Soukupova J, Janatova M, Zemankova P, Kleiblova P, Novotny J, Konopasek B, Chodacka M, Brychta M, Sochor M, Smejkalova-Musilova D, Cmejlova V, Kozevnikovova R, Miskarova L, Argalacsova S, Stolarova L, Lhotova K, Borecka M, Kleibl Z.
    • Cancers (Basel). 2019 May 28;11(6). pii: E738. doi: 10.3390/cancers11060738.
    • Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
    • Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.
    • Breast Cancer Res Treat. 2019 May 22. doi: 10.1007/s10549-019-05264-2. [Epub ahead of print]
    • Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer.
    • Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32424. [Epub ahead of print]
    • Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    • Sávolt Á, Cserni G, Lázár G, Maráz R, Kelemen P, Kovács E, Győrffy B, Udvarhelyi N, Vörös A, Ormándi K, Mátrai Z.
    • Eur J Surg Oncol. 2019 May 16. pii: S0748-7983(19)30454-8. doi: 10.1016/j.ejso.2019.05.016. [Epub ahead of print]
    • A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
    • Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.
    • Cancers (Basel). 2019 May 13;11(5):665. doi: 10.3390/cancers11050665.
    • Breast cancer risk in BRCA1/2 mutation carriers and non-carriers under prospective intensified surveillance.
    • Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    • Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32396. [Epub ahead of print]
    • Who should get a contralateral prophylactic mastectomy for breast cancer?
    • Bedrosian I, Parker PA, Brewster AM.
    • Cancer. 2019 May 1;125(9):1400-1403. doi: 10.1002/cncr.31915. Epub 2019 Jan 15.
    • Case report, review
    • A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
    • Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group.
    • Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18.
    • High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    • Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    • Breast Cancer Res Treat. 2019 May;175(1):217-228. doi: 10.1007/s10549-019-05152-9. Epub 2019 Feb 6.
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review

    Comment, Letter:

    Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers.

    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    • Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M.
    • Breast Cancer. 2019 Apr 12. doi: 10.1007/s12282-019-00971-6. [Epub ahead of print]
    • Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
    • Ansari N, Shahrabi S, Khosravi A, Shirzad R, Rezaeean H.
    • Lab Med. 2019 Apr 11. pii: lmz009. doi: 10.1093/labmed/lmz009. [Epub ahead of print]
    • Review
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review.
    • O'Leary TR, Shriver CD, Wind G.
    • Mil Med. 2019 Apr 2. pii: usz049. doi: 10.1093/milmed/usz049. [Epub ahead of print]
    • Case report, Review
    • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    • Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM.
    • Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.
    • Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
    • Lubinski J, Huzarski T, Gronwald J, Cybulski C, Debniak T, Sun P, Kim SJ, Kotsopoulos J, Narod SA.
    • Breast Cancer Res Treat. 2019 Apr;174(3):769-774. doi: 10.1007/s10549-018-05076-w. Epub 2019 Jan 5.
    • BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
    • Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI.
    • Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11.
    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study.
    • Golan O, Amitai Y, Barnea Y, Menes TS.
    • Breast Cancer Res Treat. 2019 Apr;174(2):463-468. doi: 10.1007/s10549-018-05077-9. Epub 2018 Dec 3.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2019 Mar 25;17:11. doi: 10.1186/s13053-019-0111-y. eCollection 2019.
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer.
    • Meijer TG, Verkaik NS, van Deurzen CHM, Dubbink HJ, den Toom TD, Sleddens HFBM, De Hoop EO, Dinjens WNM, Kanaar R, van Gent DC, Jager A.
    • JCO Precis Oncol. 2019 Dec [2019 Mar 11];3:1-12. doi: 10.1200/PO.18.00268.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
    • Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.
    • Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

    Editorial:

    Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

    • BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
    • Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, In Chan U, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX.
    • Hum Mol Genet. 2019 Mar 1;28(5):842-857. doi: 10.1093/hmg/ddy398.
    • Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    • Sønderstrup IMH, Jensen MB, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Laenkholm AV.
    • Acta Oncol. 2019 Mar;58(3):363-370. doi: 10.1080/0284186X.2018.1539239. Epub 2019 Jan 7.
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?
    • Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A.
    • Crit Rev Oncol Hematol. 2019 Mar;135:66-75. doi: 10.1016/j.critrevonc.2019.01.016. Epub 2019 Jan 30.
    • Review
    • Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
    • Caulfield SE, Davis CC, Byers KF.
    • J Adv Pract Oncol. 2019 Mar;10(2):167-174. Epub 2019 Mar 1.
    • Review
    • A new paradox for pCR in BRCA mutation carriers.
    • Rounis K, Mavroudis D.
    • Transl Cancer Res. 2019 Mar;8(Suppl 2):S99-S102. doi: 10.21037/tcr.2018.10.25.

    Original research:

    BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    • Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA.
    • Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • Subtypes in BRCA-mutated breast cancer.
    • Sønderstrup IMH, Jensen MR, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Lænkholm AV.
    • Hum Pathol. 2019 Feb;84:192-201. doi: 10.1016/j.humpath.2018.10.005. Epub 2018 Oct 17.
    • BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival.
    • Huszno J, Kołosza Z, Grzybowska E.
    • Oncol Lett. 2019 Feb;17(2):1986-1995. doi: 10.3892/ol.2018.9770. Epub 2018 Nov 28.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.
    • Hendrix RJ, Lee C, Friedrich AK, Rouanet E, Larkin AC, LaFemina J.
    • Clin Breast Cancer. 2019 Jan 31. pii: S1526-8209(19)30050-3. doi: 10.1016/j.clbc.2019.01.008. [Epub ahead of print]
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • Improving outcomes for young women with breast cancer: fertility and childbearing issues.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 7.

    ClinicalTrials.gov: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) (NIH. ClinicalTrials.gov.)

    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    • Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group.
    • Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22.
    • A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    • Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y.
    • Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.
    • Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    • Fremd C, Jaeger D, Schneeweiss A.
    • Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
    • Review
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    • Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.
    • Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.

Continue to Older References